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Abstract 
Lung cancer is one of the most common cancers with small lung cancer (SCLC) representing 
14% of the total lung cancer incidence. It is the major cause of cancer death in the UK. Most 
patients present with extensive disease, which is difficult to treat with the standard 
chemotherapy. Liposome-based approach provides a tool for improving treatment outcomes. 
Liposome is versatile tool, with tuneable features such as composition, size and charge. It can be 
used as a targeting therapy.  
The aim of this study was to synthesis a targeted liposomal drug delivery system for SCLC 
that enhances delivery to GRPR+ cells through conjugation with an antagonist peptide, 
cystabn. To do that, the receptor expression evaluated in the SCLC cell line (H345) and 
NSCLC cell line (A549) by indirect antibody detection using flow cytometed. The cystabn 
peptide was synthesised using Fmoc-SPPS and coupled to DSPE-PEG2000-Maleimide. The 
dyalised product was characterised by HPLC, UV and MALDI-TOF MS. PEG-stabilised 
control liposomes were prepared using the thin film hydration method and characterized by 
DLS. A targeted liposome formulation was prepared by including 1 mole % DSPE-PEG2000-
cystabn in the control formulation. Fluorescent liposomes include 1 mole % DHPE-
fluorescein. Cell uptake was measured on by flow cytometer. 
Uniform targeted liposome formulation were prepared with good stability. The cystabn 
peptide showed no growth stimulation in H345 and A549 cells, both of which have been 
shown to express GRP-R to varying extents. Uptake of targeted liposomes into SCLC cells 
was equivalent for control and targeted formulations. This indicates that the current 
formulation approach is inappropriate for the preparation of targeted liposomes.  
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 Small cell lung cancer (SCLC) 
Lung cancer is the second most common malignancy after prostate and breast cancer in men 
and woman respectively in the UK [1]. However, it is the major cause of cancer deaths 
among cancer patients [2]. SCLC is a type of lung cancer with unique clinical and 
histological features in comparison to other lung cancers, which are collectively called non-
small cell lung cancer (NSCLC).  
SCLC accounts for about 14 % of all diagnosed lung cancer cases [3] and is considered the 
most aggressive subtype of lung cancer. SCLC has a strong association with tobacco 
smoking with more than 95% of SCLC patients presenting with a history of tobacco smoking 
[4]. There is a slight decrease in SCLC incidence recognized in relation to tobacco smoking 
cessation [5]. There have been limited advances made in the treatment and understanding of 
the underlying biology of SCLC compared to NSCLC. In order to address this problem, it is 
crucial to draw efforts on to further our understanding of the biology as well as diagnosis 
and development of effective treatment for SCLC.  
1.1.1 Clinical Presentation  
SCLC is characterized by its distinct features such as its high proliferation rate, high 
probability of early metastasis and high initial response rates to chemotherapy [4]. These 
characteristics relate to the patient symptoms presentation. For example, most SCLC patients 
(~80%) present with extensive metastatic disease at the time of diagnosis although at the 
time of diagnosis relatively mild symptoms such as cough and dyspnoea are the most 
common findings in addition to symptoms related to metastasis [5].  
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SCLC is a neuroendocrine type of cancer, which produces a number of hormone-like 
substances and growth factors. The neuroendocrine nature of SCLC often leads to 
paraneoplastic syndromes such as inadequate antidiuretic hormone homeostasis [6]. 
Generally, these syndromes are groups of symptoms, which manifest themselves at body 
sites distal to that of the causative malignancy and they result from substances produced by 
the tumour itself. The syndrome symptoms take diverse manifestations, which could be, for 
example, endocrine, neuromuscular or musculoskeletal in nature [5-7].  
1.1.2 Histology of SCLC  
SCLC is a lung tumour that originates from small, monomorphic epithelial cells which 
develop undistinguishable nuclei and clear nuclear chromatin and minimal cytoplasm [3] 
(Figure 1.1). In general, SCLC can be diagnosed with high reliability based on pathological 
samples viewed using light microscopy Figure 1.1. The SCLC cells form a dense cell 
population with granular nuclear chromatin, frequent mitoses and with no nucleoli in 
addition to scarce cytoplasm. 
 
Figure 1.1: High magnification light micrograph of primary SCLC tumour cells. The 
image taken from [3].  
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For some cases however, immunohistochemistry as well as cytology is used to aid 
differential diagnosis. SCLC can be classified pathologically into two types including typical 
SCLC and combined SCLC (C-SCLC, SCLC + NSCLC), which represents about 18% of 
the cases [8]. Figure 1.2 shows the SCLC tumour sample under the light microscope, which 
show extensive necrosis and densely packed sheet of malignant cells.  
An accurate pathological diagnosis of SCLC is key as it will direct the course of treatment 
and disease prognoses. For example, SCLC is treated mostly with chemotherapy of 
platinates and etoposide in combination for limited stage disease. Consecration of thoracic 
radiotherapy if the disease can be encumbered with the thoracic radiation or the patient is 
responding to chemotherapy but showing toxicities. For metastatic disease the same protocol 
without radiotherapy and with continues monitoring throughout the treatment course. the 
patient with the extensive stage can be treated with thoracic radiotherapy, if there a complete 
response at distal sites and partial thoracic response to chemotherapy [9].  
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Figure 1.2: Low power light micrograph of SCLC primary tumour. The biopsy was taken 
from the tumour periphery and includes regions of high mitoses juxtaposed to the necrotic 
core. The used stain is hematoxylin and eosin (H&E). Image adapted from [3].   
SCLC, which is a type of neuroendocrine tumours, produces many growth factors. For 
example, gastrin-releasing peptide (GRP) [10], bombesin [11] and insulin growth factor [12] 
are expressed by SCLC in autocrine manner to stimulate its own growth. 
1.1.3 Bombesin-like peptide family in SCLC 
GRP is part of a group of peptides called bombesin-like peptides (BLPs) which bind to the 
bombesin receptor family. Bombesin is a 14-amino acid peptide first isolated from frog skin 
[13]. BLPs include GRP and neuromedin B (NMB) which were found in mammalian cells 
[14, 15]. GRP and bombesin share a highly conserved 7-amino acids C-terminal sequence 
(shown in Figure 1.3), which is essential for high-affinity to GRP-R [14]. GRP is a 
neuropeptide that acts through gastrin-releasing peptide receptor (GRP-R) in human to 
perform numerous functions around the body such as in the gastrointestinal and central 
nervous systems, including release of gastrointestinal hormones and epithelial cell 
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proliferation by acting as a hormone [16]. There is growing interest in the bombesin receptor 
family for a number of reasons. First, this family of receptors, particularly GRP-R , has been 
shown to be overexpressed in a wide spectrum of human cancers, as well as it found to be 
involved in tumour growth in various tumours [17].   
 
Figure 1.3: amino acids sequence of two peptides- Bombesin(1-14)  (top) and GRP(14-27) 
(bottom).  The 7-amino acids shared sequence between the two peptides is highalited with 
blue rectangle. 
The human GRP-R is a G-protein coupled receptor comprising 384 amino acids and seven 
transmembrane regions (Figure 1.4). Human GRP-R expressed in the pancreas, the stomach, 
prostate, skeletal muscle and in the CNS. C-terminal 7-amino acids sequence shared between 
Bombesin and GRP is the shortest sequence required to cause internalization [18]. Bombesin 
and GRP bind to GRP-R, which is a G-protein coupled receptor. This triggers the activation 
of many signalling pathways that transduct the mitogenic signal to the nucleus and promote 
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cell proliferation. For example, bombesin stimulated Ca2+ mobilization [19] and activation 
of protein kinase C [20]. In regard to internalization, GRP-R has been shown to be 
internalized upon ligand binding by fluorescence visualization of the receptor trafficking 
[21].  
 
Figure 1.4: The three mammalian bombesin receptors represintation. Gastrin releasing 
peptide receptor (GRP-R), neuromedin B receptor (NMB-R) and Bombesin receptor subtype 
3 (BRS-3) are shown as amino acids sequences. Repressive structure for GRP-R across cell 
membrane shown in the bottom right. It features the seven receptor subunits of this G-protein 
pound receptor.  
GRP was found to be a potent mitogen in cancers such as SCLC [22], breast [23], colon [24] 
and prostate [25] cancers. NMB has also been found to stimulate growth in SCLC cells in 
vitro [26]. GRP-R  is reported to be overexpressed in numerous cancers such as lung, colon, 
and prostate [17]. SCLC cells express the receptors, GRP-R , NMB-R and the orphan BRS-
3, and also secrete the cognate ligands, GRP and NMB [27]. These receptor-ligand pairs 
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have been shown to fulfil an autocrine growth loop that is unique to malignant cells. Normal 
lung epithelia dose not express GRP-R [28]. GRP is a 27-amino acid peptide that shows 
extensive homology with bombesin (57 %) that binds with high affinity (KD = 1.3 nM) to 
solubilised GRP-R in the NCI-H345 (H345) SCLC cell line [29]. Ligand-receptor binding 
in this cell line was later (Corjay et al) shown to cause raised intracellular Ca2+ levels 
consistent with the mechanism of a protein kinase C, G protein linked GPCR [30].  
The expression of GRP-R has been evaluated in a variety of human cancers such as SCLC 
by RT-PCR and immunoreactivity experiments. GRP-R has been shown to be expressed in 
17/20 SCLC cell lines (Toi-Scott et al 1996) 85% , which found to be more than other 
Bombesin receptors in the cells, (NMB-R = 55%, BB3-R = 25%) [27]. GRP-R was also 
detected in  primary SCLC samples (2/5; 29%) in another study [31]. There is evidence in 
the literatures in regard to GRP-R expression in NSCLC.   GRP-R found to be expressed in 
11/13 NSCLC cell lines [27]. The growth of NSCLC tumour in mice was suppressed by 
more than 30% using GRP-R antagonist [32].  Taken together the expression data for GRP 
and GRP-R in SCLC offers the opportunity to target this pathway for cancer treatment. 
1.1.4 Staging of SCLC 
Cancer staging aims to identify the magnitude of cancer cell dissemination. This is one of 
the most important factors in making successful treatment decisions and subsequently 
disease prognosis. Patients with SCLC are typically grouped into limited stage or extensive 
stage disease [4]. Limited stage disease is generally defined as a case where the tumour(s) 
are to one half of the thorax, with hilar and mediastinal nodes metastases, which can be 
treated with one tolerable radiotherapy session. Extensive stage disease is any presentation 
of the disease not labelled as limited stage. Most (65%) patients present with extensive stage 
disease and the median survival and 5 years survival for this stage are 7–12 months and 2% 
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of the initial diagnosed patients, respectively. For the limited stage disease, 23 months’ 
median survival and 12–17% survive 5 years after the initial diagnosis. In the UK the TNM 
staging system is used for a more detailed analysis of the disease. It includes the size of the 
tumour (T), whether or not the cancer cells have metastasised to local lymph nodes (N) and 
whether the tumour has metastasised distally (M) [33].  
1.1.5 Treatment 
Combination chemotherapy is the standard treatment for both limited and extensive stages 
of SCLC. Etoposide and cisplatin plus chest radiotherapy for patients with good performance 
status and limited-stage disease is the first line therapy.  Good performance status is 
determined by using a scale for assessing cancer progression, its effects on the daily activities 
of the patient [34]. In general, this treatment approach for limited stage has complete initial 
treatment response rate of 80% or higher, increased median survival period, and increased 
5-year cancer-free survival before tumour reestablishment.  In contrast, patients with 
extensive stage disease show only 20% response rate and the median survival extends to 7-
8 months with a the 5-year cancer-free survival of 2%. Surgical resection of early stage 
SCLC can extend the 5-year survival to 35–40%, if followed by chemotherapy, chest 
radiotherapy or both. These statistics highlight the need to improve treatment using novel 
strategies for early diagnosis and treatment [35-37]. 
 Cancer Targeting  
According to the “magic bullet theory” by Paul Ehrlich, drugs can be selectively targeted 
toward molecular targets specific to cancer cells [38]. The main advantage of the targeting 
approach is to enhance drug accumulation in the cancer tumour while limiting the unwanted 
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toxicity to healthy tissues. In general, there are two ways to target anticancer drugs to the 
desired site of action, which include passive and active targeting strategies. Passive targeting 
is achieving by utilizing enhanced permeability and retention (EPR) effect (Figure 1.5). This 
approach exploits the defective vascularisation of solid tumours which display increased 
permeability to particles in the nanometre range. This leads to enhanced penetration into the 
tumour mass and prolonged retention within the tumour due to inefficient penetration back 
into the vasculature or lymphatic drainage [39]. Active targeting of cancer tissue can be 
achieved by directing drug delivery platforms toward receptors in the tumour cells that are 
overexpressed on their surface. Optimal active targeting requires the presence of a highly 
specific tumour receptor that is not expressed of highly under-expressed in non-target 
(healthy) tissue. Any expression of target receptor in other tissues could result in off-target 
effects and significant toxicity. Furthermore, a stable expression of the target molecule is 
required to avoid down regulation of the receptor in cancer cells [40]. It is difficult to find 
the ideal target, however, there are many targeted cancer therapies developed to percent with 
great clinical potential. The targeted delivery of nanomaterials can overcome many 
difficulties encountered with free drugs, including insolubility, rapid clearance, degradation, 
lack of selectivity and nonspecific toxicity as well as reducing the drug dosage. 
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Figure 1.5: Schematic representation of the enhanced permeability and retention (EPR) 
effect. Passive targeting is achieved by using EPR. Leaky tumour vascular with impaired 
lymphatic drainage, increase permeability to nanoparticulates. This image adapted from 
[41].  
1.2.1 GRP-R as a target in SCLC  
Recognising GRP-R as a tumour target a number of groups have developed peptide ligands 
and antibodies targeting GRP and GRP-R. Cuttitta et al [42] showed in 1985 that an antibody 
raised against GRP could block GRP binding to its receptor and subsequently blocked clonal 
growth of SCLC cells in vitro and xenograft growth in vivo. This antibody (named 2A11) 
was later confirmed by Avis et al to bind to the peptide with high affinity and was taken 
forward into a number of pre-clinical [40] and later clinical trials, reaching Phase II [43].  
  
In a complementary approach other labs have developed antagonistic peptides that bind the 
GRP-R, thus blocking ligand binding and autocrine growth stimulation. For example, one 
non-natural peptide sequence termed RC-3095 is a potent antagonist to the GRP-R receptor 
which decreased by 50–70% the tumour volume of xenografts in nude mice following 
subcutaneous administration for 5 weeks [44]. A third approach to the treatment of GRP-R 
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positive tumours involves the conjugation of a cytotoxic drug (doxorubicin) to a bombesin-
derived peptide antagonist (RC-3094) which binds with high affinity to the GRP-R [45]. 
This approach, which has the benefit of smaller molecular weight and lower immunogenicity 
was also reported to inhibit growth of H69 SCLC xenografts in vitro and in vivo [155]. 
There are some synthetic antagonists are produced to bind with high affinity to GRP-R. A 
study used two GRP-R antagonistic peptides ([d-Cpa1-β-Leu8-des-Met9]litorin and [d-Phe6 
, Leu13-CH2NH-Cpa14]bombesin(6–14)) showed inhibition in growth both in vitro and in 
vivo using GRP-R positive SCLC (SCLC 41M and SCLC 75) [46].  The first GRP-R 
antagonist used in the study was developed from litorin (pGlu-Gln-Trp-Ala-Val-Gly-His-
Phe-Met-NH2), which is an amphibian Bombesin-like peptide. Another study showed that a 
number of GRP-R antagonist peptides caused inhibition in the growth of SCLC cell line 
(NCI-H345 cells) as well as in mice [47].  Llinares et al synthesised GRP-R antagonist 
(JMV594) (H-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-NH2) by solution phase peptide 
synthesis. The peptide tested on rat pancreatic acini and Swiss 3T3 cells. The antagonist 
recognize the GRP-R receptor on pancreatic acini (binding 34 ± 14 nm) and antagonized 
GRP stimulated amylase secretion (IC50 = 190.0 ± 57 nm) and also able to recognize the 
GRP receptor in 3T3 cells (binding Ki 18.9 ± 8.1 nm) [48]. In another study, the selectivity 
of the JMV94 for GRP-R (IC50 = 2.2 ± 0.1 nm) was demonstrated over the NMB-R (IC50 
= >10,000 nm) by using competitive cell binding assay on Balb/c 3T3 cells transfected with 
ether receptors [49]. Marsouvanidis et al developed the JMV594 peptide further by 
coupling the chelator DOTA (1,4,7,10 tetraazacyclododecane-1,4,7,10-tetraacetic 
acid) to the N-terminal end of the peptide by using (βAla)2 as linker and labelled it 
with 111In. The 111In-DOTA-(βAla)2-JMV594 showed internalized to some extent in 
PC-3 prostate cell line at37 °C. More than 60% of the radiopeptide remained intact 
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for 5 min after entering the bloodstream of healthy mice. The radiopeptide also 
showed high tumor uptake and rapid background clearance via the kidneys [50]. 
 Liposomes as drug delivery platforms 
1.3.1 Definition and background 
Alec Bangham discovered closed bilayer structures [51], which were called liposomes later 
by Sessa [52].  Bangham discovered that when phospholipids are dispersed in water, they 
form a bilayer vesicle that he termed multilamellar smectic mesophases. Since then, 
liposomes have gained much interest and contributed to many areas such as pharmaceutics, 
cosmetics and food science such as in the treatment of cancer [53], anti-ageing creams [54] 
and flavour retention agent [55] respectively.  At first, liposomes were used as a model 
membrane system in the area of biophysical research before moving to the pharmaceutical 
industry to be used as drug carriers after Gregoriadis’ demonstration of their drug-carrying 
capacity [56].  
Liposomes are self-assembled artificial colloidal spherical vesicles composed of one or more 
bilayers of amphiphilic molecules called phospholipids (Figure 1.6). Liposomes can 
transport hydrophilic or hydrophobic drugs, depending on the nature of the drug. Liposomes 
are classified according to their bilayer number into multilamellar vesicles (MLV) and 
unilamellar vesicles (ULV). ULV subclassified into large unilamellar vesicles (LUV) and 
small unilamellar vesicles (SUV). Liposomes range in size from tens of nanometres to tens 
of micrometres. Liposomes are commonly used as drug delivery carriers for a number of 
reasons. They are biocompatible, biodegradable and they have the capacity to encapsulate 
both hydrophilic and hydrophobic drugs.  
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Figure 1.6: schematic representation for liposome and a component phospholipid. 
Liposome vesicles consist from aqueous core, in which hydrophilic molecules can be 
encapsulated and phospholipid bilayer, in which lipophilic molecules can be encapsulated. 
The bilayer consists mainly from amphiphilic phospholipids. Phospholipids consist from 
hydrophilic head (phosphate group) and hydrophobic fatty acid chains joined together by a 
glycerol molecule. The phosphate molecule can be modified for instance by choline to form 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), which shown in the left of the figure. 
The liposome image modified from [57].  
1.3.2 Liposomes for targeting 
Liposomes can be designed to target specific cell types. In cancer drug delivery, there are 
two types of targeting, which include passive and active targeting. This can be done by 
designing liposomes in a size range of 100 nm to 200 nm, which promote the accumulation 
in the target tumour site. Smaller liposomes in the size range of 20 nm are cleared by kidney 
glomerulus and larger liposomes (>200 nm) tend to be  recognised and cleared by the 
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reticuloendothelial system (RES) [58]. For the active targeting, functionalization of the 
liposomal surface with antibodies, ligands and other biomolecules is used encourage 
selective liposomal interaction with the targeted cells. This can improve cellular drug 
accumulation by increasing the local concentration of drug in the vicinity of the target call 
and thus increase passive drug uptake into the cell. Alternatively, the liposome encapsulated 
drug can be delivered directly into the cell by internalisation / endocytosis. Liposomal 
composition and physical characteristics, such as size and surface charge, are crucial 
determinants to the liposome stability and application [59-61].   
1.3.3 Liposome role in enhancing the pharmacology of the drug  
Liposomes greatly improve the drug pharmacokinetics, pharmacodynamics and toxicity 
profile when compared to the free drug [62]. Non-targeted liposomal anticancer drug 
formulations of the appropriate size passively accumulate in tumour tissues by the EPR 
effect and this is associated with greater amounts of drug in tumour tissues compared to free 
drug. For example, Doxil®, a pegylated liposomal doxorubicin offers unique 
pharmacokinetic profile compared to free drug (Figure 1.7) 
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Figure 1.7: Plasma pharmacokinetics of free doxorubicin compared to liposomal 
doxorubicin (Doxil®). Figure adapted from [63]. 
The liposomal carrier (Doxil®) slowed the plasma clearance combared to the free drug from 
45 L/h to 0.1 L/h in patients after IV dose of 25 mg/m2 or 50 mg/m2  of both free and 
liposomal drug.  Doxil® also showed smaller volume of distribution combared to free drug 
(4 L versus 254 L respectively). The liposomal drug also enhanced the drug level in the 
tumer to > 4 folds [63]. Doxil is an example of a “stealth liposome” in which a hydrophilic 
PEG polymer shields the liposomal surface in such a way to reduce detection by the immune 
system and rapid clearance by the mononuclear phagocyte system (MPS) [64, 65].  
1.3.4 Phospholipids – the building blocks of liposomes 
Phospholipids are naturally occurring amphiphilic molecules that contribute to cellular 
membrane of prokaryotes and eukaryotes. The basic unit of a phospholipid (Figure 1.6 
above) comprises two fatty acids, a glycerol molecule and a phosphate group that it generally 
modified with a small organic molecule. The fatty acid tails impart a hydrophobic character 
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that is contrasted by the hydrophilic character if the glycerophosphate unit. Together these 
characteristics promote amphiphilic characteristics which allow self-assembly into complex 
structures such as bilayers, multilayers and vesicle like structures. The variation in these 
components, either naturally through biosynthesis or synthetically through hydrogenation, 
affords a wide range of phospholipids [66].  
The chemical structures of phospholipids can be classified by the alcohol molecule 
(glycerophospholipids and sphingomyelins), head group (e.g. phosphatidylethanolamine 
(PE), phosphatidylserine (PS)), the length and the saturation of hydrophobic side chains; the 
type of bonding between the aliphatic moieties and alcohol backbone; and the number of 
aliphatic chains [66]. This variability in phospholipid structure is an important factor in 
designing the drug delivery system as it affects the assembly and physio-chemical properties 
of the system.  In aqueous media, phospholipids can form many kinds of assemblies, such 
as spherical micelles, cylindrical micelles, liposomes, planar bilayers and inverted micelles, 
depending on the molecular shapes of the phospholipids. Bilayer preferring lipids, such as 
PC, are usually used to form liposomes via self-assembly. However, non-bilayer lipids, such 
as unsaturated PE, can be incorporated to certain extent in a bilayer structure, which is 
stabilized by bilayer preferring lipids [66].  
1.3.4.1 Cholesterol 
Another very important factor in the liposomal composition and design is the addition of 
cholesterol. Cholesterol is naturally occurring hydrophobic sterol with four hydrocarbon 
rings and a pendant branched aliphatic chain (Figure 1.8). The presence of the hydroxyl 
group (OH) gives it weak amphiphlic character which facilitates insertion into the lipid 
bilayers of eukaryotic cell membranes with its hydrophilic part oriented towards the aqueous 
medium, and the rigid hydrophobic ring structure toward the bilayer interior (Figure 1.8). 
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Cholesterol enhances bilayer stability and reduces aggregation by modulating the bilayer 
rigidity.  Cholesterol also act as permeability buffer by controlling the fluidity of liposomal 
membrane. It changes the molecular packing and dynamics in the fluid crystalline and gel 
phases. Below the phase transition temperature (TC) of lipids, cholesterol addition increases 
the fluidity of lipids, while above TC the mobility and fluidity of the lipid chains are 
restricted, reducing the bilayer permeability and drug incorporation efficiency. The 
membrane elasticity found to be increased with an increase in cholesterol content. The 
maximum amount of cholesterol that has been reported and can be incorporated into 
liposome is widely assumed to be about 50 mole %. However, the optimal ratio between 
cholesterol and lipid is not understood. The most frequently used proportion is 2:1 ratio or 
1:1 ratio lipids to cholesterol parts [67].  
 
Figure 1.8: Schematic representation of cholesterol insertion into a phospholipid bilayer. 
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1.3.5 Liposome classification 
Liposomes can be classified according to their size and lamellarity into multilamellar 
vesicles (MLVs, 0.1–20 μm), large unilamellar vesicles (LUVs, 0.1–1 μm) and small 
unilamellar vesicles (SUVs, 25–100 nm) [68]. The size and lamellarity of liposomes depends 
on their composition and their method of preparation. MLVs are more suitable for lipophilic 
drug encapsulation due to their increased lamellarity which provides a larger volume into 
which hydrophobic drugs can partition. On the other hand, LUVs and SUVs are more 
suitable for parenteral administration due to their homogenous size distribution. However, 
the smaller the size of the vesicles the lower the amount of encapsulation of hydrophilic 
drugs.  
The traditional method of making MLVs is the thin film hydration technique. The lipidic 
components are dissolved in organic solvent (e.g. chloroform and methanol) followed by the 
removal of the organic solvents using a rotary evaporator to produce a thin lipid film. The 
addition of an aqueous phase above the phase transition temperature of the lipid mixture 
with shaking results in the formation of the MLVs [69].  
Extrusion of MLVs through polycarbonate membrane filters was an important 
methodological development in SUV/LUV manufacture. This method allows the production 
of homogenous vesicles with improved trapping efficiency. Moreover, using a reverse phase 
evaporation method or ethanol-based proliposome technology, oligolamellar vesicles (0.1–
1 μm) have been produced. The manual extrusion system with relatively low pressure is 
usually used for lab scale production. For large scale production, higher pressure systems 
were developed. The production of SUVs with diameters less than 50 nm is only possible 
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using sonication or homogenization. However, for a large scale production of SUVs in the 
20 nm to 50 nm size range, microfluidic mixing techniques can be used [59].  
Liposome can also be classified according to their compositions to four general classes of 
liposome for delivery of drugs. These include conventional liposomes, sterically-stabilized 
liposomes, ligand-targeted liposomes and stimuli-responsive liposomes. Traditionally, 
liposomes were formulated from phospholipids and cholesterol with neutral, cationic, or 
anionic phospholipids as well as cholesterol. Further developments led to the formulations 
of the other types of liposomes [61].  
1.3.6 Factors affecting the efficacy of liposomal drug delivery systems 
Factors such as lipid composition, size and surface charge are important in determining the 
properties of liposomes and their clearance route from the body. Liposomes can range in size 
from 10 nm to 5 µm. Adjustment of the size of the nanoparticles is crucial to take advantage 
of the EPR effect. In vivo, nanoparticles generally within the size range of 20 nm to 400 nm 
will diffuse through the gaps in the cancer vascular endothelium, which is not the case in 
normal tissue. The porous nature of the cancer vasculature varies in size depending on the 
cancer type, site, and the stage of the disease, but the upper size threshold is generally around 
300 to 400 nm. In addition, nanoparticles must be larger than 10 nm to avoid kidney first 
pass elimination and smaller than 150 to 200 nm to avoid clearance by the liver and spleen 
[60].  
Liposome opsonisation and clearance by the reticuloendothelial system (RES) is dependent 
on vesicle composition and size. RES is part of the immune system and their main function 
is to eliminate foreign materials from the blood. RES consists of cells such as blood 
monocytes and macrophages found mainly in liver, the lung and the spleen. Naked 
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phospholipid liposomes can be rapidly cleared by RES cells due to coating of liposomal 
surface with serum proteins called opsonins. Large liposomes (>200 nm in diameter) are 
rapidly opsonised and taken up by the RES. Opsonisation decreases with a reduction in 
liposome size. Small liposomes have a relatively larger surface area, and will have a lower 
density of opsonins on the membrane surface which results in lower uptake by the 
macrophages. Liposomes with a size of 70 to 200 nm will have a greater chance to escape 
from RES and remain in the circulation longer and then reach the target. Due to extravasation 
through the fenestrated capillary walls in the liver, the small liposomes (< 70 nm in diameter) 
show shorter circulation time and therefore reduced drug activity [70].  
1.3.7 From conventional to targeted liposomes 
Rapid clearance of naked phospholipid liposomes by RES typically limits their application 
to therapies such as immune-related medicine (e.g. liposomal hepatitis A vaccine). To 
address the problem, coating the liposome surface with inert, biocompatible polymers, such 
as PEG was suggested and adapted [71, 72]. Polymer flexibility is an important factor 
because it allows a relatively small number of grafted polymers to protect the liposomal 
surface. In addition, polymer coated liposome, such as pegylated liposome, provide stability 
to the colloidal liposomal system through steric repulsion and decreased aggregation.  A 
recently discovered drawback of pegylated liposomes is their activation of the complement 
system. As a consequence of this, it can give hypersensitivity reactions and decrease 
circulation time due to clearance by RES [73].  
With the development of Doxil an improvement of clinical parameters was observed [74]. 
The passive targeting of tumours via the EPR effect was inefficient due to drug release in 
sites other than the tumour. The formulation of targeted liposomes for cell-specific targeting 
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was proposed (Figure 1.9) as a means to delivery drug only to the tumour site. The major 
challenge is the identification of biological targets that are expressed exclusively or 
significantly over-expressed by cancer cells.  
The targeting moiety could be antibody, peptide or carbohydrate-based. The used of the 
monoclonal antibodies as targeting moieties is one of the most effective methods for 
liposome targeting due to the exquisite specificity of antibody-antigen interactions. 
However, it has some disadvantages such as difficulty of production due to bulky nature, 
immunogenicity and poor pharmacokinetic profile. The use of peptides as targeting moieties 
is one of the good approaches because of its small size, ease of synthesis and modification 
such as attachment to pegylated lipids [61, 75].  
 
Figure 1.9: representation of the Pegylated and targeted liposomes. On the left side, the 
liposome is coated with peg polymer and on the other side the liposomes features targeting 
moiety. The targeting moiety% can be controlled and the nature of the moiety can be varied 
such as using peptides or antibody. The image adapted from [76] 
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Tethering of targeting peptides to pegylated lipids offers the advantages of simultaneous cell 
targeting while maintaining the steric stabilisation afforded by polymer grafting. Typically 
the peptide is presented on the surface of the liposome surface (via a spacer which separates 
the phospholipid head group) or at the terminal end of the polymer (e.g. PEG) chain. Further 
development of this approach evolved into the concept of stimuli-responsive liposomes. For 
example, pH-sensitive liposomes release their content in a pH-sensitive manner inside the 
target cells by incorporating pH-sensitive components. Following cellular internalisation of 
the intact liposome the endosomal pH decreases causing a conformational of chemical 
change in the liposomal system that destabilises the membrane and permits drug release into 
the endosomal lumen and subsequent diffusion into the cytoplasm [59-61, 70].  
 Liposomal delivery in SCLC 
SCLC is a challenging disease in terms of both diagnosis and management/treatment. We 
hypothesised that a GRP-R targeted liposomal delivery system could be developed for 
enhanced delivery of cytotoxic drugs to the primary and metastatic tumours. Towards this 
aim it was necessary to confirm the expression of GRP-R in lung cancer cells and to develop 
a prototypical targeted liposome that bears an efficient targeting peptide for GRP-R. To 
achieve therapeutic efficacy, it was necessary to study stability in simple formulation buffers 
as well as physiological media such as serum.  Such a delivery system could be delivered 
locally to the tumour site before and after surgical resection of the primary tumour in order 
to localise the delivery of drug to the tumour site. Alternatively, parenteral administration of 
such a system would rely on the efficient homing of the targeted liposomes to distal tumour 
sites. 
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Aims and objectives of this thesis: 
 To evaluate the GRP-R expression in SCLC cell line (H345) and NSCLC cell 
line (A549) 
 To synthesise cystabn-targeted liposome toward SCLC cells 
 Evaluate cell uptake by fluorescently labelled liposomes 
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MATERIALS AND METHODS 
2 Chapter 
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 Introduction 
This project aimed to develop a targeted liposomal formulation for the treatment of small 
cell lung cancer (SCLC). This chapter provides the general information of the source of 
materials used through the project, the sample preparation procedures and theoretical 
background and methodology development of the characterisation methods used. The GRP-
R receptor targeting peptide (cystabn) was synthesised using Fmoc-SPPS before coupling to 
a commercially available pegylated lipid. The peptide and conjugate was characterised by 
HPLC, UV and MALDI-TOF MS. The cystabn-PEG-lipid conjugate was included in 
targeted at 1 mole % using the thin film hydration method and the liposomes characterized 
by DLS. The stability of targeted and control liposomes in buffer solution and biological 
media was also studied by DLS. Targeting of SCLC cells with cystabn peptide was examined 
using flow cytometry analysis of fluorescent liposomes which included 1 mole % DHPE-
fluorescein.  
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 Manual Fmoc solid phase peptide synthesis (SPPS) 
The classical solution phase synthesis (SPS) of peptides has several disadvantages. These 
include the need to remove intermediates and reaction by-products at each step of peptide 
growth; the requirement to characterise the purified product at each step; and, poor solubility 
of some intermediate peptides in the synthesis solvent. The standard SPPS, introduced by 
Merrifield in 1963, is a convenient and efficient method for peptide production that utilises 
solid insoluble polymeric resin beads as a support covalently bonded with the growing 
peptide chain [77]. The peptide chain is constructed from the C’ terminal end by the step-
wise addition of amino acids that are alpha amino-protected by Fmoc group, as illustrated in 
(Figure 2.1). Orthogonal functional groups within the amino acid are typically protected by 
acid-sensitive protecting groups (e.g. Boc or trityl) in order to avoid their interference with 
the coupling of the required α amino and carboxylic acid groups to form a peptide bond [78]. 
Examples of amino acid side chains that are protected include the side-chain (ε) amine of 
lysine or the δ side chain carboxylic acid group of glutamic acid. 
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Figure 2.1: General solid phase peptide synthesis scheme, where P-AA-OH represents a 
Nα-terminal and side-chain protected amino acid and H-AA-OH represents an unprotected 
amino acid. The first amino acid is loaded onto a solid support, the N-terminal protection 
group is removed and the subsequent amino acid is coupled. At the end of the synthesis the 
peptide is cleaved from the solid support and fully deprotected [79]. 
The use of an insoluble, high porosity resin allows for high peptide loading and the removal 
of unreacted coupling reagents and by-products by simple filtration and washing. In addition, 
this method is highlighted by short coupling reaction time, simplicity of set-up and 
automation using robotic liquid handling. Other advantages include the flexibility of resin 
attachment chemistries. For example, cyclic peptide synthesis is achievable through by 
coupling the first amino acid to resin through a side chain carboxyl group. Limitations 
include a decrease in the peptide coupling efficiency with growing chain length and potential 
for aggregation. This results in reduced final purity and yield of the peptide [80]. 
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2.2.1 Amino Acid Protecting Groups 
Modern SPPS generally uses the Fmoc approach. This is an orthogonal approach in which, 
for example, a base-labile Fmoc group is used to protect the alpha carbon primary amine and 
an acid-sensitive protecting group is used to protect other side chain functional groups which 
could either interfere with peptide chain growth (e.g. the carboxylic acid in Asp or Glu) or 
when side chains are sensitive to modification by the synthesis conditions e.g. the oxidation 
of tryptophan residues. The Fmoc group is base sensitive and can be cleaved using mild 
conditions such as 20% piperidine or 5% piperazine after successful peptide coupling. There 
is an extensive range of orthogonal protecting groups for amino acid side chains which are 
generally acid-sensitive and are cleaved at the end of the synthesis. For example, the Boc 
protecting group is labile to treatment with TFA but is stable to base treatment during Fmoc 
removal. In addition to that, the resin linker, which covalently links the resin beads with the 
C-terminal amino acid, should typically be cleavable under the acidic deprotection 
conditions of the side chains protecting group. Therefore, the choice of the Nα-protecting 
group will define the choice of the side chains protection and the linker, thus it also define 
the name of the SPPS technique (Fmoc SPPS or Boc SPPS). Boc SPPS, initially introduced 
by Merrifield, require TFA to be removed from the alpha amino group and highly toxic 
hydrogen fluoride for the final peptide to be cleaved from the resin. However, Fmoc SPPS 
require milder and safer conditions [81].  
Moreover, new resin derivatives have been developed, which allowed broader scope for 
chemical synthesis. For example, enhanced degree of polymer crosslinking promotes 
optimal stable swelling of the resin and increased loading.  In addition to that, development 
of super-acid sensitive resin-peptide linkers allows the cleavage of peptides from the resin 
which retain all necessary side chain protecting groups. These cleaved products can be 
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further coupled or processed, before side chain deprotection at the end of the procedure. The 
choice of linker also provide the opportunity to determine the C-terminal functionality such 
as free carboxylic group (e.g. chlorotrityl resin) or amide group (e.g. Rink Amide resin) [80]. 
2.2.2 The SPPS synthetic cycle 
The C-terminal Nα-protected amino acid is anchored to the insoluble resin by the addition of 
peptide coupling agents. After filtration to remove excess synthesis reagents and by-products 
only correctly coupled peptide remains on the resin. Prior to coupling of the next amino acid 
a deprotection step involving the removal of the base-labile Nα-protecting group is required. 
After washing to remove base, the next Nα-protected amino acid is linked to the resin-bound 
C terminal amino acid by coupling reagents. This cycle is repeated until the peptide chain 
completed (Figure 2.1). When designing the synthesis procedure of a natural linear peptide 
sequence it is imperative to use amino acid reagents with all necessary orthogonal side chain 
protecting groups to the allow selective coupling of the alpha amino and carboxylic acid 
groups. At the end of the synthesis these orthogonal protecting groups are cleaved from the 
washed and dried resin with a cocktail of trifluoroacetic acid (TFA) and scavenger 
molecules. These scavenger molecules prevent reattachment of orthogonal protecting groups 
and modification of deprotected side chains under the harsh cleavage conditions. The choice 
of scavenger cocktail depends on the primary sequence of the peptide. For example, the 
orthogonal protecting groups of methionine, cysteine histidine and tryptophan are easily 
removed but the deprotected side chains are labile in acid conditions. Some side chain 
protecting groups e.g. Mtr protecting group of arginine undergoes very slow acid-mediated 
cleavage and therefore requires scavengers to drive the deprotection reaction to completion. 
Finally, some protecting groups are extremely reactive once cleaved and therefore need to 
be sequestered by scavengers to prevent modification of the deprotected peptide [80]. 
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2.2.3  Choice of coupling agents 
The key step in peptide synthesis is amide bond formation by coupling between the Nα-
protected carboxylic acid moiety and the amino group of the anchored peptide chain. The 
first coupling reaction forms a peptide bond between the resin amino group and the C-
terminal amino acid of the peptide sequence. In this work, Rink Amide resin was used to 
liberate a C terminal amidated peptide after cleavage. Scheme 2.1 shows the reaction 
between the resin and the Fmoc-protected amino acid.  
 
Scheme 2.1: the reaction between the Rink Amide resin and the Fmoc-protected amino 
acid. 
The first step in this reaction is the activation of the carboxylic acid moiety of the Nα-
protected amino acid followed by amide bond formation. These two steps can be ether 
performed consecutively or at once depending on the choice of the coupling reagent.  
Couplings are achieved via formation of an active ester of the Fmoc- amino acid followed 
by attack of the peptide chain's alpha amino group (Scheme 2.2). This can be done by 
reacting the amino acid with a coupling reagent to form a stable reactive intermediate.  
Secondly, the intermediate can be attacked by a nucleophile such as the amino group of a 
carboxy-protected amino acid.  
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Scheme 2.2: reaction scheme of amino acid activation by nucleophile and coupling 
reaction. The base deprotonates the carboxylic acid. The carboxylate anion then attacks the 
electron deficient carbon atom of HBTU. The resulting HOAt anion (1-Hydroxy-7-
azabenzotriazole) reacts with the newly formed activated carboxylic acid derived 
intermediate to form an OAt- activated ester. The amine reacts with the OAt activated ester 
to form the amide. 
Many coupling agents are available for the formation of these active ester, including 
carbodiimides (DIC, EDCI), uronium salts (HBTU, HATU) and phosphonium salts (PyBOP, 
PyAOP). Each of these coupling agents has advantages and disadvantages including, for 
example, high coupling efficiency and low racemisation or, on the contrary, high cost and a 
propensity to propensity to favour racemisation of chiral amino acids. Aminium coupling 
reagents (e.g. HCTU) are among the most potent coupling reagents used in Fmoc SPPS 
method. They are commonly used as in situ activators in the presence of tertiary amine as a 
base (e.g. NMM, DIPEA). The base serve as proton extractor from the carboxylic acid 
moiety to facilitate the intermediate formation. However, this increase the rate of 
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racemization, which can be suppressed by the use of an auxiliary nucleophile (e.g. HOBt) as 
an additive (Scheme 2.2) [82].  
In this work HCTU was used to maximise coupling efficiency while limiting high costs that 
are associated with the use of modern reagents such as PyBOP.  The coupling reaction 
typically involves the use of a 4-8 fold excess of both coupling agents, base and amino acids 
in order to drive the reaction to completion. It is not uncommon, however, for the coupling 
reaction to be incomplete after a single coupling reaction step so a second reaction with fresh 
base, coupling agents and base is performed. This maximises the yield of intact peptide and 
avoids complex purification of multiple reaction products that include truncated peptide or 
those with missing residues.  Following a second coupling step the resin is tested for reaction 
completion using a colourimetric Kaiser test. 
 
2.2.4 The Kaiser test:  
The Kaiser test is a convenient colourimetric test to detect the presence of free amines on 
the SPPS resin. It is used to qualitatively confirm successful completion of two key steps in 
the SPPS process. Firstly, successful Fmoc deprotection should reveal a free alpha amino 
group which gives a positive Kaiser result. i.e. reaction of the ninhydrin with primary amines 
generates an extended conjugated network which is blue and colours the resin beads. 
Successful peptide bond formation removes the free alpha amino group by coupling to the 
incoming Fmoc-protected AA. This results in a negative Kaiser test i.e. non-blue resin beads.  
The test is performed by mixing a small sample of resin with two drops of Kaiser Reagent 
A (5% ninhydrin in ethanol (w/v)) and two drops of Kaiser Reagent B (80% phenol in 
ethanol (w/v) + KCN in pyridine as 2 mL 0.001 M KCN in 98-mL pyridine) in a 
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microcentrifuge tube and heating to 95 °C for 2 min. Extended heating will give a false 
positive result due to Fmoc removal by reaction with pyridine [83, 84]. 
 Cystabn peptide characterization 
Crude cystabn peptide was characterized in terms of its purity, molecular weight and 
concentration using HPLC, MALDI Tof MS and UV spectroscopy techniques respectively. 
The following section will discuss the theoretical principle and general methods used 
regarding these techniques. 
2.3.1 HPLC 
HPLC is the standard technique for the characterization of peptides and proteins. Advantages 
of this method include high reproducibility and ease of protocol optimisation. It relies on the 
loading of an analyte (peptide) onto a stationary phase (e.g. octadecyl silica, C18) column 
through which a pressurized liquid (mobile phase) is pumped. This allows the separation of 
compounds through interaction with the stationary phase. This interaction is slightly 
different for each component in the sample. As a result, the elution rate of the components 
will vary which leads to separation on the column stationary phase. The nature of the 
interaction can be hydrophobic, dipole–dipole and ionic, or a combination. There are three 
types of HPLC methods typically used in peptides separation. These include size-exclusion 
HPLC, ion-exchange HPLC and reversed phase (RP)-HPLC, which rely on differences in 
size, net charge and hydrophobicity respectively. Silica-based stationary phases are used 
most frequently because it offers good particle rigidity and stability, allowing the use of high 
mobile phase flow rates and efficient separation.  
 
Chapter 2 
 
 
54 | P a g e  
 
RP-HPLC is the standard method for peptide separations. It is preferred over other HPLC 
types because of its high resolution, speed, operation under wide range of conditions, 
reproducibility, durability of the stationary phase for long period of time and efficiency. 
However, it has the disadvantage of irreversible denaturation of some large peptide / protein 
samples, which leads to loss of biological activity. RP-HPLC involves the separation of 
molecules on according to their hydrophobicity. The separation is due to the hydrophobic 
binding of the solute molecule from the mobile phase to the modified packed stationary 
phase particles. The elution from the column occur by a gradient or isocratic conditions of 
aqueous and organic mobile phases. Therefore, solute elution can be manipulated by 
changing hydrophobic interactions. This can be achieved through changing the column 
temperature, the use of TFA or any ion-pairing modifier, or the composition of the aqueous 
and organic mobile phase. RP-HPLC can be used for analytical purposes (i.e. checking 
peptide purity) or for recovery and purification of peptides from synthesis reaction mixtures. 
This choice of analytical or preparative method will generally require the same mobile and 
stationary phase conditions but an increase in the size of the stationary phase column and an 
increase of flow rate to achieve efficient separation and recovery of peptide [85].   
2.3.2 MALDI ToF MS 
After the introduction of soft ionization methods, mass spectrometry has become feasible 
tool for biomolecules analysis. The two major techniques are electrospray ionization and 
matrix assisted laser desorption ionization (MALDI). When these techniques combined with 
time-of-flight (TOF) mass spectrometry, it produce affordable efficient methods for analysis 
of biological and organic molecules in laboratories. MALDI was introduced in 1988 by 
Karas and Hillenkamp as a revolutionary method for analysing the fragile biomolecules [86]. 
MALDI MS preferred over ESI MS because it usually generates monocharged ions which 
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make it easy to interpret, while the later tend to produce multiply charged ions especially 
with large molecules which requires data deconvolution downstream from sample 
acquisition. However, MALDI MS can be problematic for small molecules analysis as it 
produces considerable background in the m/z range less than 800, which is attributed to 
ionization of the matrix.  
In principle, MALDI MS proceeds by firstly dissolving the non-volatile analyte with a large 
excess of small organic molecules called matrix in a volatile solvent. This helps to prevent 
aggregation of the analyte, which can prevent efficient desorption. Co-crystallization of a 
few microliters of the mixed sample performed on a metal plate by allowing the solvent to 
evaporate. The plate placed in the MALDI MS instrument under high vacuum. The sample 
then irradiated with a pulsed laser beam (usually 337 nm). This allow the matrix molecule 
to absorb most of the laser energy in the UV region in the form of heat. The analyte molecule 
is preserved intact due to the large excess of matrix. This absorption of energy causes analyte 
sublimation and expansion into a dense gas cloud. The gaseous molecules of the matrix along 
with the adsorbed analyte molecules travels rapidly toward the detector under high vacuum. 
The MALDI MS can be equipped with a Time of Flight (ToF) analyser, which feature more 
rapid analysis with high resolution and sensitivity [87].  
2.3.3 UV Spectrophotometric determination of peptide concentration: 
The lyophilized peptide usually contain non-peptide molecules such as water, salts, absorbed 
solvents, and counter ions. An accurate peptide concentration can be determined by 
quantitative amino acid analysis or UV spectrophotometry. If the peptide primary sequence 
contains a strong chromophore (e.g. tryptophan, tyrosine) the peptide concentration can be 
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determined conveniently using the extinction coefficient of these residues using the 
following equation: 
   



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Equation 2.1: for peptide concentration calculation. Where A280 = the absorbance of the 
solution at 280 nm in a 1-cm cell, MW = molecular weight of the peptide, #Trp = number of 
tryptophan residues in the sequence and #Tyr = number of tyrosines in the sequence. The 
extinction coefficients of chromophoric residues at 280 nm at neutral pH using a 1-cm cell 
are 5560 AU/mmole/ml for tryptophan and 1200 AU/mmole/ml for tyrosine  [88, 89].  
 Conjugate Synthesis 
The targeting peptide (cystabn) was conjugated to one of the lipids components (DSPE-
PEG2000-Maleimide) for targeting the liposomes to SCLC cells. The use of a spacer PEG 
between lipid and peptide is crucial to allow steric stabilisation of the liposomes and to 
efficiently present the peptide to cell surface receptors.  
A great number of attachment chemistries exist for the conjugation of targeting peptides to 
pegylated–lipids. These include conjugation by thiol–maleimide, or strain-promoted 
(copper-free) azide–alkyne ‘click’ chemistry. Alternatively, it is possible to couple the lipid 
to the peptide N’ terminus at the end of the SPPS procedure using an amine reactive N-
hydroxysuccinimide ester [90-92].  
Conjugating the peptide and PEG-lipid components during the SPPS phase has some 
disadvantages. These include potentially low yield, especially with long PEG chain and its 
poor suitability for cyclic peptides. The other peptide conjugation methods are dependent on 
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the choice of functional groups for both peptide residues and PEG, which match the chosen 
conjugation chemistry. One of the most commonly used methods is the thiol-maleimide 
conjugation (scheme 2.3). In this method, the peptide chain must feature thiol functional 
group typically by adding a cysteine residue at the N-terminal end, which then reacts with 
the maleimide moiety on a functionalized PEG-lipid after peptide cleavage and purification. 
The thiol-maleimide Michael addition reaction is very reactive due to selectivity of the thiol-
maleimide reaction in aqueous and organic media when performed at pH 6.5 -7.5  [93, 94].  
 
Scheme 2.3: Schematic of the synthesis of thiol-maleimide reaction. 
In addition to that, it is rapid reaction with formation of stable product. The high reactivity 
of the carbon-carbon double bond in maleimide is due to the bond angle distortion and the 
ring strain [95-97].  
 Liposomes preparation 
In this study, targeting and control liposomes synthesized by thin film hydration method 
followed by freeze-thawing and extrusion to produce monodispersed unilamellar vesicles. 
A major aspect in liposome medical application is the efficient loading of drug needed to 
achieve therapeutic effect. Liposomes allow encapsulation of both hydrophilic and lipophilic 
molecules in the hydrophilic core and lipid bilayer respectively. Encapsulation process can 
be passive (i.e. during liposomes preparation) or active (i.e. after liposomes preparation). 
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The passive strategy depends on factors including the composition of the formulation, zeta 
potential, particle size and preparation method. Active loading of compounds into the 
liposome core via ion/pH gradients enables high concentrations of reagents to be stored 
within vesicles. Many weak acids and bases, such as doxorubicin, can be actively loaded 
with high efficiency up to concentrations of 130 mM [59, 61]. 
2.5.1 Thin film hydration 
There are several factor affecting the choice of the liposomes preparation method. These 
include the physicochemical characteristics of the liposomal formulation and the 
encapsulated material, the dispersion medium; optimum size, polydispersity and shelf-life 
of the vesicles for the intended application. There are three broad types of liposomes 
preparation methods including mechanical dispersion, solvent dispersion and detergent 
removal method [59].  
One of the simplest procedure for the liposome formation is the thin film hydration method, 
although it is often limited by low encapsulation efficiency. The liposomes are prepared, in 
this method, by mixing and dissolving in a round bottomed flask the individual lipid 
components of the liposomal formulation in an organic solvent. The non-polar organic 
solvents used typically include chloroform or a mixture of chloroform and methanol for the 
more polar lipid derivatives such as pegylated lipids. The organic solvent is then removed 
by evaporation under vacuum, to produce a thin layer of lipids in the bottom of the flask. 
Traces of organic solvents which may interfere with liposome assembly are removed under 
high vacuum. The lipid film is hydrated using aqueous buffer which contains the cargo 
molecule of choice. Upon agitation, the lipids swell and hydrate to form a heterogeneous 
suspension of MLVs. A less polydisperse vesicle dispersion can be generated by a freeze-
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thawing technique which involves repeated cycles of rapid freezing in a dry ice-acetone bath 
then rapid thawing at a temperature exceeding the gel-liquid crystalline phase transition. The 
production of refined monodispersed unilamellar liposomes requires energetic input by 
extrusion through membrane filters of defined diameters (e.g. 400, 200, 100 nm) or through 
sonication at high frequency (Figure 2.2) [98-100].  
 
Figure 2.2: Schematic representation of liposome synthesis by thin film hydration method 
followed by freeze-thawing and extrusion techniques. Adapted from [101]. 
Liposome downsizing can be achieved by sonication or extrusion. Sonication is a commonly 
used method for the preparation of unilamellar vesicles (ULV). In this method, MLV break 
up into smaller vesicles by sonic energy. The size of the vesicles depends on the time of 
sonication as well as other factors such as lipid composition, concentration, temperature, and 
sonication power. This method is easier to perform in a shorter time compared to extrusion. 
However, issues with poor batch-to-batch size reproducibility are not uncommon. The other 
widely used method for ULV preparation is extrusion. It is achieved by forcing the lipid 
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suspension through a polycarbonate membrane with a well-defined pore size to produce 
vesicles with a characteristic diameter near the pore size of the membrane used in preparing 
them. The advantages of this method are good batch-to-batch reproducibility and no 
requirement to eliminate organic solvents or detergents removal from the final preparations. 
The exact mechanism of vesicle formation during extrusion is incompletely understood.  
However, it is clear that MUVs deform into the filter pore due to the applied pressure. This 
leads to transient rupture and resealing of the vesicles, which contribute to their downsizing 
during extrusion. A common practice is to apply multiple cycles of freeze thawing onto the 
suspension prior extrusion. This will lead to an easier and smoother extrusion due to the 
decrease in lamellarity caused by this method. All downsizing methods must be performed 
above the lipids’ gel-fluid transition temperature to produce the desired size distribution. 
This is because the lipids fluidity decrease under this temperature [102-105]. 
 Liposomes Characterization 
In order to evaluate the liposome synthesis quality and to ensure reproducibility, various 
parameters can be measured. The most important parameters are the size and surface charge 
of liposomes. They give information about the physical stability of the product. In this study, 
each liposomal formulation was characterized by Zetasizer Nano Zs, for its size using 
dynamic light scattering (DLS) and its zeta potential using electrophoretic light scattering 
(ELS).  
2.6.1 Size analysis by DLS 
There are two important parameters to evaluate physical stability of liposomes intended for 
therapeutic use. These are the size and surface charge. Several techniques are available for 
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assessing the average size of liposomes and its disruption which include microscopy 
techniques, size-exclusion chromatography (SEC), field-flow fractionation and static or 
dynamic light scattering. One of the most commonly used method is DLS, also called photon 
correlation spectroscopy (PCS) [106, 107]. DLS measures the dynamic size disruption of 
particles suspended in liquid indirectly from their diffusion coefficient (D) using Stokes-
Einstein equation (Equation 2.2).     
𝐷 =
𝑘𝐵  𝑇
6𝜋𝜂Rℎ
 
Equation 2.2: The Stokes-Einstein equation, where (Rh) is the radius of the suspended 
sphere that have the same diffusion coefficient (D) as the particle, (T) is the absolute 
temperature of the suspension, (η) is the viscosity of the liquid and (kB) is Boltzmann’s 
constant (1.38x10-23 J/K). 
As shown in the Figure 2.3, DLS works by radiating a beam of laser light onto particles 
suspended in liquid, which result in the scattering of the light in all directions as it interact 
with the particles. The scattered light detected by a detector, which is positioned classically 
at angle of 90° or at the backscatter angel of 173°. The detected scattered light produce a 
speckle pattern at the detector surface due to interference of light waves. The particles are in 
continuous motion due to their interaction with the molecule of liquid dispersant. This 
motion, which is called the Brownian motion, produce a fluctuation in the intensity of the 
detected light and the speckle pattern moves accordingly. The rates of that fluctuation in the 
light intensities caused by the apparently moving pattern are detected by the detector and 
converted into dynamic size distribution by using computer algorithms. 
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Figure 2.3: Schematic representation of DLS instrument. A laser (e.g. He-Ne laser 633nm) 
radiated into the suspended particles in the sample and the light scattered and detected at 
an angle (e.g. 173°). The correlator uses algorithms to produce the autocorrelation curve 
from the intensity signals and based on that the particle size distribution produced using 
Stokes-Einstein equation. Image adapted from [108]. 
In a DLS instrument, a digital correlator, calculates the autocorrelation function for the 
detected photons and plot intensities against time. This fluctuation of intensities with time is 
random due to the random Brownian motion of the suspended particles. For a relatively large 
particles or high viscosity medium, the motion (diffusion) of the particle will be slow and 
lead to slow fluctuation in intensities as function of time and vice versa. Subsequently the 
diffusion coefficient can be calculated from the correlation function using Equation 2.3. 
 
 
speckle 
pattern  
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Γ = 𝑞𝐷 
Equation 2.3: diffusion coefficient equation. Г is the exponential decay rate and q is the 
modulus of the scattering vector (defined by the scattering angle and wavelength of light). 
Finally, the hydrodynamic radius can be calculated using the Stokes‐Einstein equation. 
DLS method have several advantages including the ability to make measurements in the 
native sample environment, simplicity of operation, sample easily prepared with low 
volumes. In addition, it covers the size range from few nanometres to few micrometres range. 
However, the technique does not yield particle shape information because it gives the 
diameter of sphere that diffuses the same way as the particle regardless of the particle shape. 
It also can yield a bias towards reporting larger diameters when small quantities of 
aggregates or impurities are present in the sample. This is because, the presence of the larger 
particles will dominate the light scattering signal and mask the presence of the smaller 
particles because scattering intensity is proportional to the sixth power of the particle 
diameter [109, 110]. 
2.6.2 Zeta potential:  
One of the most important factors for any colloidal system is the surface charge. Most 
colloidal dispersions in aqueous media carry an electric charge. The charge between 
similarly charged particles lead to repulsion between these particles. This repulsion gives 
stability for the suspended particles in an aqueous media. The surface charge is produced by 
several factors. Firstly, ionization of surface moieties could lead to negative, positive or 
zwitterionic charges. Furthermore, the charge could be generated from the adsorption of 
charged species on the particle surface leading to negatively or positively charged surface 
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depending on the surfactant nature. The overall charge around the particle surface in a 
particular medium can be calculated indirectly by zeta potential. This physical property is 
the potential difference between the medium and the charged layer surrounding the particles 
(Figure 2.4).  
 
Figure 2.4: DLVO energy graph. Van der Waals (dashed line) and electrostatic double 
layer (dotted line) contribute to total DLVO forces represented versus the separation 
distance between two spheres (d). 
This charged layer is from the attracted molecules from the dispersion medium. Zeta 
potential are commonly used to predict the stability of colloidal systems. If all the particles 
in suspension have a large negative or positive zeta potential, then they will tend to repel 
each other and there will be reduced tendency to aggregation. However, if the particles have 
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low zeta potential values then there will be not enough force to prevent the particles from 
aggregating. 
The zeta potential of a colloidal system is measured by applying an electric field in a process 
called electrophoresis. The particle charge dictates the direction and velocity of its motion 
caused by the electric field. It is also affected by the surrounding medium and the strength 
of the electric field. In Zetasizer instruments (Figure 2.5), a laser beam is irradiated through 
optical set up, which split the beam into two beams: the scattering beam which passes 
through the suspension and a reference beam which passes around the sample cell. The two 
beams cross each other and create fluctuations in intensity due to particles’ motion and create 
a speckle pattern.  This is termed laser Doppler electrophoresis. 
 
 
Figure 2.5: Optical configuration of the Zetasizer Nano series for zeta potential 
measurements. 
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This frequency of the modulated beam can be used to measure the particle mobility by 
comparing it with frequency of the reference beam. In conclusion, the laser Doppler 
electrophoresis method is used to measure the frequency shift. This shift is due to the 
movement of particles produced by application of electric field. Equation 4 is used to 
calculate the shift: 
∆𝑓 = 2𝑣 sin (
𝜃
2
 )/𝜆 
  
Equation 2.4: frequency shift equation. ∆𝑓 is the frequency shift, v is the particle velocity, 
λ the laser wavelength and θ the scattering angle. 
In Zetasizer Nano ZS, a new variation of this technique is used. This technique is called 
phase analysis light scattering (PALS). Instead of measuring the change in frequency of the 
modulated beam in comparison to reference beam, the phase difference is measured. 
Basically, it is a measure of the change in phase of the modulated beam relative to a reference 
beam. The phase is a measure of frequency x time. So, the rate of phase shift between the 
two signals is measured. From which, the mean phase shift is calculated and then the mean 
zeta potential is calculated [109, 111-116]. 
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 Cell lines 
2.7.1 H345 cell line 
The NCI-H345 cell line is a human epithelial lung cells line derived from bone marrow 
metastasis of small cell lung cancer. The cells were derived from 64 years old Caucasian 
male in 1981 by D. Carney, A.F. Gazdar. This cell line grow in vitro as multicell aggregates 
in a gland-like clusters in suspension. The viability of the cells in clusters is better than the 
viability of the single cells in the cultures. These cells found to be producing gastrin releasing 
peptide (GRP) as well as expressing its receptor [117]. 
2.7.2 A549 cell line 
A549 cells are adenocarcinoma human alveolar basal epithelial cells. These cells established 
in 1972 from a 58-year-old caucasian male [118] from which, a malignant lung tumour was 
removed and cultured. These cells grow in vitro as adherent monolayer cells. A549 cells 
have the ability to synthesize lecithin with high level of unsaturated fatty acids [119].  The 
cell line are widely used as an in vitro model for a type II pulmonary epithelial cell model 
for drug metabolism and as a transfection host [120]. The A549 cell line has previsously 
been classified as a NSCLC model [121]. 
 MTS cell assay 
The MTS assay is a cell proliferation colorimetric assay. It reports cellular viability by 
measuring the absorbance of a coloured formazan product produced in the mitochondria.  
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Figure 2.6: MTS reduction scheme by reductases in the mitochondria of live cells. 
The MTS reagent is reduced by NADH or NADPH to a water soluble product in the presence 
of phenazine methosulfate (PMS) as electron coupling agent (Figure 2.6). The 
NADH/NADPH cofactors are produced by dehydrogenase enzymes in the metabolic 
pathways of viable cells.  This characteristic can be used for sensitive quantification of viable 
cells. The coloured product produced by viable cells can be quantified by measuring the 
absorbance at 490-500 nm. The assay can be used for the measurement of cell proliferation 
in response to growth factors, cytokines, mitogens, and nutrients, etc. It can also be used for 
the analysis of cytotoxic compounds like anticancer drugs and many other toxic agents and 
pharmaceutical compounds. MTS assay is performed by adding the MTS/PES reagent 
mixture directly into the cell culture media of 96-well microtiter plate. Incubation at 37 ºC 
and absorbance reading without the washing or solubilisation steps involved in the MTT 
assay [122-124]. 
 
 
 
Chapter 2 
 
 
69 | P a g e  
 
 Flow cytometry 
Flow cytometer is a technique designed to allow counting and detection of specific cells and 
their elements in a mixture of cells suspension such as blood.  This is achieved by the 
carefully coordinated components of the flow cytometer including fluidics, optical, and 
electronic systems (Figure 2.7). The fluidics system of the instrument is the key component. 
Because at this stage the cells are injected into the sheath fluid stream and hydrodynamically 
focused into a single file at the centre of the stream. Each cell in the stream exited by a light 
source, typically a laser beam, at a certain point called interrogation point. This lead to light 
scattering as well as fluorescence. The scattered light in the forward direction is detected by 
the forward scatter channel. This scattering intensity depends on the refractive index and 
membrane permeability of the cell membrane as well as the cell size.  The light scattered at 
90° detected by the side scattering channel.  The intensity of this light is proportional to the 
extent of the cytosolic structures in the cell.  The study of both forward and side scattering 
allow the differentiation between different cell types by size and internal complexity. If cells 
were also labelled with fluorochrome-linked antibodies the cell associated fluorescence 
travels through the optic system to be filtered and detected with the detector with appropriate 
fluorescence emission settings. The florescent intensity is proportional to the number of 
fluorochrome molecules in each cell. Flow cytometers are equipped with more than one 
florescence detector in addition to the forward and side scattering detectors, which allow 
cells to be labelled with more than one fluorochrome[125-127].   
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Figure 2.7: schematic representation of a flow cytometer instrumentation setup. There are 
two detectors for the scattered light: forward scatter detector and side scatter detector. 
There are also a number of photomultiplier tubes (PMT) to detect florescence (e.g. FL-1 to 
FL-4). Image adapted from [128].  
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SYNTHESIS OF GRP-R TARGETED LIPOSOMES 
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 Introduction 
To date there are no clinically approved liposomal formulations that include an active 
targeting motif for tumour cells [61]. In recent years, however, two antibody-drug conjugates 
(ADCs) - Kadcyla® (Trastuzumab (Herceptin) targeting HER2+ breast cancer) and 
Adcetris® (Brentuximab targeting CD30+ Hodgkin’s lymphoma)- have been approved 
which specifically target tumour cells to deliver the potent tubulin inhibitors, vedotin and 
emtansine, respectively [129, 130]. As is the case for ADCs, active targeting of liposomes 
has the potential of directing the therapeutic system toward specific diseased target cells. 
The passive targeting method, even though it offers enhanced therapeutic profile via 
decreasing toxicity and enhance drug biodistribution by EPR effect and pegylation, it is 
limited by the variability in the degree of tumour vascularization and porosity of tumour 
vessels [131, 132]. The active targeting method offers the potential for superior therapeutic 
index by increasing the targeting and accumulation of the delivery system in the target 
tumour tissue [133, 134]. The attached targeting motif on the surface of the nanoparticle 
should bind to its cognate binding partner (e.g. protein, receptor) on the target cell and 
preferably be internalised into the cell, from where the drug may be liberated into the 
cytoplasm. Ideally, the target “receptor” should be specific to the target and overexpressed 
on its surface and trigger endocytosis upon ligand binding [135]. [136-140]. [139, 141].  
In this chapter, the GRP receptor was targeted on SCLC cells using a peptide antagonist. The 
targeting peptide would be presented on the liposomal surface and would afford intracellular 
delivery of cargo molecules into the target cells. 
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The aims of this chapter were to: 
1) Confirmation of GRP-R expression in NCI-H345 SCLC and A549 
adenocarcinoma cells 
2) Synthesis and characterisation of the targeting cystabn peptide and preparation 
of a cystabn-DSPE-PEG2000 conjugate 
3) Preparation of control (untargeted) and cystabn-targeted liposomal 
formulations 
4) Assessment of liposomal stability in different aqueous media 
 
 Materials & methods 
3.2.1 Materials 
All materials were of analytical grade and sourced from either Sigma or Fisher unless 
stated otherwise.  
Table 3.1: Antibodies for GRP-R expression 
Product Supplier Catalogue No. 
Rabbit polyclonal antibody to human GRPR 
(GRPR antibody [N2C3]) 
GeneTex GTX113209 
Donkey anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor® 488 conjugate 
ThermoFisher Scientific A-21206 
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Table 3.2: Materials for Cystabn synthesis 
Product Supplier Catalogue No. 
Rink Amide resin (100-200 mesh) Merck Millipore 855001 
 (Fmoc-L-Val-OH) AGTC Bioproducts Ltd AGM20 
 (Fmoc-L-Trp(Boc)-OH) AGTC Bioproducts Ltd AGM18 
 (Fmoc-L-Leu-OH) AGTC Bioproducts Ltd AGM11 
 (Fmoc-L-His(Trt)-OH) AGTC Bioproducts Ltd AGM09 
 (Fmoc-L-Gln(Trt)-OH) AGTC Bioproducts Ltd AGM06 
 (Fmoc-L-Cys(Trt)-OH) AGTC Bioproducts Ltd AGM05 
 (Fmoc-L-Ala-OH*H2O) AGTC Bioproducts Ltd AGM01 
 (Fmoc-Gly-OH) AGTC Bioproducts Ltd AGM08 
 (Fmoc-D-Phe-OH) AGTC Bioproducts Ltd AG-140-139-1170 
Fmoc-(3S,4S)Sta-OH Iris Biotech FAA1630 
HCTU AGTC Bioproducts Ltd AG330645 
HOBt. H2O AGTC Bioproducts Ltd AG123333 
DIPEA For Peptide Synthesis AGTC Bioproducts Ltd AG-BC7012 
Dichloromethane (DCM) Sigma-Aldrich® 24233 
Triisopropylsilane (TIPS) Sigma-Aldrich® 233781 
Trifluoroacetic acid (TFA) Fisher Scientific 10294110 
1,2-Ethanedithiol (EDT) Sigma-Aldrich® 02390 
DMF Peptide Synthesis Grade  AGTC Bioproducts Ltd AGDMF 
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Table 3.3: Materials for DSPE-PEG2000-Cystabn conjugate synthesis 
Product Supplier Catalogue No. 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[maleimide(polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG2000-Maleimide) 
Avanti® Polar 
Lipids, INC. 
880126 
L-cysteinyl-D-phenylalanyl-L-glutaminyl-L-
tryptophyl-L-alanyl-L-valyl-L-glycyl-L-histidyl-
(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-
Leucinamide (Cystabn) 
In-house 
synthesis and 
custom synthesis 
by  Cellmano 
Biotech Ltd 
- 
 
Table 3.4: Materials for liposome formulation 
Product Supplier Catalogue 
No. 
1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) (18:1 (Δ9-Cis) PC) 
Avanti® Polar 
Lipids, INC. 
850375 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-2000] 
Avanti® Polar 
Lipids, INC. 
880130 
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(ammonium salt) (DOPE-PEG2000) (18:1 
PEG2000 PE) 
Cholesterol (Ovine wool, >98%) Avanti® Polar 
Lipids, INC. 
700000 
DSPE-PEG2000-Cystabn In-house 
conjugation 
- 
(N-(Fluorescein-5-Thiocarbamoyl)-1,2-
Dihexadecanoyl-sn-Glycero-3-
Phosphoethanolamine, Triethylammonium Salt) 
(Fluorescein DHPE) 
ThermoFisher 
Scientific 
F-362 
 
3.2.2 Cell Culture 
All cell cultures were maintained at 37 °C, 5 % CO2, and 95 % air in a humidified incubator 
and routinely passaged at 80% confluency (A549) or weekly (H345). 
3.2.2.1 H345 cell line 
The human epithelial metastatic SCLC cell line (NCI-H345) used in this study overexpresses 
the GRP-R [17, 142, 143] and grows in suspension as multicellular aggregates. H345 cells 
were grown in RPMI 1640 media supplemented with 10 % FBS, 5 mM L-glutamine, 100 
units/ml penicillin, and 100 µg/ml streptomycin (hereafter called full medium). H345 cells 
were passaged by centrifugation at 200 g for 5 min. The supernatant was removed and the 
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pellet re-suspended in fresh media and counted manually using haemocytometer before 
passaging it onto the required culture surface (2 × 105 cells/mL). 
3.2.2.2 A549 cell line 
This adherent cells were grown in DMEM medium supplemented with 10 % FBS, 100 
units/ml penicillin, and 100 µg/ml streptomycin. A549 cells passaged by washing with PBS 
(3 x 5mL) followed by trypsinization (0.25% trypsin + 1mM EDTA for 5 minutes at 37°C). 
The cells were centrifuged at 200 g for 5 min. The supernatant was removed and the pellet 
re-suspended in fresh media and counted manually using haemocytometer before passaging 
it onto the required culture surface at density of 3 × 104 cells / cm2. 
3.2.3 GRP-R expression by flow cytometer using fluorescent probe 
Both cell lines (A549 and H345) were harvested and diluted to 5 × 105 cells per mL and 
centrifuged at 1000 rpm at 25 °C for 5 min. The cell pellets were washed (x3) with PBS and 
resuspended gently in fixation buffer (4% PFA in PBS) for 30 min at RT on a tube roller. 
The suspension of each cell line was divided into two samples – permeabilized and non-
permeabilized. Permeabilized cells were resuspended in ice cold permeabilization buffer 
(0.5% Triton X-100 in PBS) and incubated for 5 min at RT under gentle rolling agitation 
before washing with PBS (x3). The nonpermeabilized cells were treated the same with the 
omission of the permeabilisation buffer (PBS used in lieu). Both samples were pelleted by 
centrifugation (1000 rpm, 5 min, 25 ⁰C) and resuspended in blocking buffer (10% FBS in 
PBS) for 10 min at RT. Wells were washed (PBS x3) and resuspended in rabbit anti-GRP-R 
antibody (GTX113209 GeneTex, UK, 1µg/ml in blocking buffer) then incubated on ice for 
30 minutes. Cells were washed (PBS x3) before incubation with the secondary antibody 
(donkey, anti-rabbit AlexaFluor 488, 0.5µg/ml in blocking buffer) on ice for 30 min. All 
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samples were washed (PBS x3) and resuspended in PBS before analysis. Analyses were 
performed using a Beckman Coulter, Cytomics FC500 flow cytometer equipped with a 15 
mW argon-ion laser. Cells were analysed on the basis of forward light scatter (FS), side light 
scatter (SS) and FL-1 intensity. Typically, fluorescence information for 10000 events was 
collected for each sample using Kaluza Analysis Software. Data were analysed by gating 
cells, as judged by FS versus SS dot plots, and plotting the fluorescence of these cells in a 
histogram. Fluorescence profiles or histograms shown were representative of those obtained 
from the number of experiments indicated. The increase in fluorescence intensity above 
background was determined by measuring the shift in fluorescence intensity from peak to 
peak, relative to the indicated control. 
3.2.4 Cystabn synthesis by manual SPPS 
Cystabn (Cys-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) and scrambled cystabn (Cys-
Ala-Gly-Val-Leu-Trp-D-Phe-Sta-Gln-His-NH2) were synthesized on the Rink Amide 
MBHA resin. Each coupling step involved addition to 1 eq. of resin Fmoc-AA, HCTU, 
HOBt and DIPEA (4:4:4:8 eq.) in 1.5 mL DMF.  The mixture was reacted for 30 min at RT 
with occasional gentle agitation then washed with DMF (x3). This process was repeated to 
achieve a “double coupling” that increases overall coupling efficiency and eventual yield. 
After confirmation of successful coupling (negative Kaiser test result) the Fmoc deprotection 
step was performed (2 x 5 min 5% piperazine in DMF). After washing with DMF (3 x 5 mL, 
1 min) Fmoc deprotection was confirmed by positive Kaiser test. This coupling and 
deprotection procedure was repeated until completion of the peptide sequence. The N-
terminal amino acid was Fmoc- deprotected, washed with DMF (3 x 5 mL, 1 min), then 
washed with DCM (3 x 5 mL, 5 min). The resin was then dried under a stream of nitrogen 
until the resin was free-flowing and dried in vacuo for 3-5 h. 
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The peptide was cleaved from the resin using a cleavage cocktail (5 ml/100 mg resin) 
comprising TFA (94 %v/v) and scavengers TIPS, EDT and water (2 % v/v each). The 
cleavage reaction was performed for 7 h to overnight at RT with gentle agitation. The peptide 
was precipitated in 50 mL diethyl ether that had been pre-chilled on a dry ice-acetone bath. 
Peptide precipitation was noticeable by the cloudy appearance of ether after slow dropwise 
addition of the cleavage mixture. In the event of slow peptide precipitation, the ether-peptide 
mix was sealed in a round bottomed flask and stored overnight at – 20 °C. Precipitated 
peptide was harvested by centrifugation (3000 rpm, 10 min, 4 °C). Peptide precipitate was 
washed (x3 cold diethyl ether) then dissolved in 10% aqueous acetic acid before 
lyophilisation until a dry powder was observed. 
3.2.5 Conjugate synthesis 
The DSPE-PEG2000-Cystabn conjugate was synthesised using thiol–maleimide 
conjugation reaction. One equivalent of DSPE-PEG2000 (6.8 μmol in 4 mL chloroform) 
was added to two equivalents of cystabn (13.3 μmol in 2 mL methanol) in a round-bottomed 
flask. The mixture was stirred for 24 h at RT under nitrogen gas. After confirmation of 
successful conjugation by MALDI Tof MS analysis the solvent was evaporated and the 
reaction mixture redissolved in milliQ water. Unreacted peptide was removed by dialysis 
against miliQ water at RT for three days (the water changed every 2 h then left overnight) 
using 2000 MWCO benzoylated dialysis tubing. The purified conjugate was lyophilised to 
a dry white powder.  
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3.2.6 Cystabn and conjugate characterization 
3.2.6.1 HPLC 
Samples were analysed using a gradient elution method using Mobile phase A (H2O + 0.1% 
TFA) and B solution (acetonitrile + 0.1% TFA) on a Perkin Elmer HPLC system comprising 
of binary solvent pump, autosampler, UV/Vis Detector and Peltier Column Oven. Mobile 
phases were membrane degassed using Millipore Vacuum filtration using 0.2 µm 
nitrocellulose filter. The gradient profile was 0-5 min. 5% B, 5-25 min 5-95% B and 5 min 
5% B. Peptide samples (~1 mg/mL in miliQ water) were prepared in HPLC vials after 
centrifugation at 13000 rpm for 10 min. Peptide was eluted on a Phenomenex Luna® C18 
(2) LC Column (particle size 5 µm, pore size 100 Å, 150 length x 4.6 mm diameter). Samples 
injected as 10 µl and analysed using UV/Vis detector at 280 nm wavelength. For the 
conjugate, the same method used with Thermo Scientific Hypersil™ BDS C8 LC  Column 
(particle size 3 µm, pore size 130Å, 150 length x 4.6 mm diameter). Samples were injected 
in 10 µl volumes and elution monitored at 280 nm. 
3.2.6.2 Development of a MALDI ToF MS method for conjugate analysis 
Peptide samples (2 mg/mL) was prepared in 1:1 acetonitrile: miliQ water + 0.1% TFA. A 
saturated matrix solution (5 mg/mL) of -cyano hydroxycinnamic acid was prepared in 1:1 
acetonitrile: water + 0.1% TFA. Equal volumes (5 µL) of the matrix and sample solutions 
were mixed together and 1 µL spotted twice onto the same well of a clean MALDI sample 
plate. Samples were left to dry for 5 min in between each drop. Samples were analysed using 
linear ion detection mode on a SHIMADZU Axima-CFR MALDI-TOF. 
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The method used for MALDI analysis of peptides was unsuitable for conjugate analysis. A 
new sample layering method was developed for conjugate sample. Briefly, the conjugate 
was dissolved in chloroform at 2 mg/mL. A saturated matrix solution (10 mg/mL) of 
universal MALDI matrix (1:1 mixture of DHB and α-cyano-4-hydroxy-cinnamic acid, 
Sigma Aldrich, Poole, UK) was prepared in methanol. The sample was applied directly as a 
1 µl spot onto a MALDI plate well followed by rapid evaporation by stream of hot air. The 
matrix solution was then applied as 1 µl on the same well followed by rapid evaporation by 
stream of hot air. The dried sample taken to be analysed by SHIMADZU Axima-CFR 
MALDI-TOF and Launchpad software. 
3.2.6.3 UV Spectrophotometry for peptide concentration determination 
Samples (~1 mg/mL & ~0.5 mg/mL) were prepared in milliQ water (for the peptide samples) 
and chloroform (for the conjugate samples) in clean quartz UV cuvettes. The samples were 
scanned at wavelengths range of 400 nm to 200 nm. The absorbance at 280 nm was used to 
determine the concentration using the molar extinction coefficient for the peptide tryptophan 
residue (5560 AU/mmole/ml). 
3.2.7 Preparation of control and cystabn-targeted liposomal formulations 
Lipids for each liposomal formulation (Table 3.5) were dissolved in chloroform and mixed 
in a round-bottomed flask. A thin lipid film was produced by evaporation of the solvent in 
vacuo. The film maintained under high vacuum for one hour to remove traces of organic 
solvent. The film was hydrated with PBS to a final lipids concentration of 10 mg/mL then 
heated to 55 ºC and vortexed extensively to produce MLVs [98]. Five cycles of freeze-
thawing (dry ice-acetone followed by heating to 55 ºC) were performed to reduce the 
lamellarity of the vesicles [99]. Finally lipid suspensions were extruded (21 x) through 
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polycarbonate membranes of 200 nm, 100 nm and 50 nm pore sizes to produce a narrow size 
distribution of ULVs [100]. 
Table 3.5: Liposomal Formulations Composition 
Control Formulation DOPC: Chol: DOPE-PEG2000 (57: 38: 5 mol. %) 
Targeted Formulation DOPC: Chol: DOPE-PEG2000: DSPE-PEG2000-Cystabn 
(57: 38: 4: 1 mol. %) 
FL-Control Formulation DOPC: Chol: DOPE-PEG2000: DHPE-Fluorescein (56: 38: 
5: 1 mol. %) 
FL-Targeted 
Formulation 
DOPC: Chol: DOPE-PEG2000: DSPE-PEG2000-Cystabn: 
DHPE-Fluorescein (56: 38: 4: 1: 1 mol. %) 
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3.2.8 Characterization of liposomal formulations 
Liposomes were characterized for size and zeta potential using Zetasizer Nano ZS. For size 
measurements the liposomal suspension was diluted 1:10 with PBS and sealed with parafilm.  
For zeta potential measurements, the liposomal suspension was diluted 1:10 with PBS and 
transferred to a clean folded capillary cell (Malvern, DTS1070).  
 
3.2.9 Liposomal stability in PBS and 10% serum 
An aliquot of the liposomal suspension was diluted 1:10 with either PBS or 10% FBS in 
PBS After 0, 24 and 72 hours the samples were transferred to cuvettes and measured for 
size and zeta potential as described above.  
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 Results 
3.3.1 GRP-R expression in SCLC cells (H345) 
To examine for differences in the GRP-R expression levels in the two cells lines an indirect 
immunolabelling was performed followed by semi-quantitative detection by flow cytometry. 
Figure 3.1 shows the flow cytometric characterisation the two cell lines, A549 and H345. 
Specifically, Figures 3.1A-B show the forward and side scatter profiles of the A549 and 
H345 lines, respectively. Subtle differences in cell size and granularity were evident from 
the different locations of the two cell line profiles on the dot plot. This was consistent with 
microscopic inspection of cell morphology (data not shown). The cells were gated based on 
FS/SS of the control cells (i.e. without treatment), and the fluorescence of these cells 
subtracted from treatment groups to yield the median fluorescence intensity (MFI) for each 
group. 
The GRP-R expression in non-permeabilised H345 (primary and secondary antibody) was 
51 ± 27 and about 5-fold greater than the MFI of the secondary-only control (10 ± 1.7) 
indicating specific labelling of surface expressed receptor. In contrast, the surface expression 
of GRP-R in A549 was lower. Specifically, the MFI was only 2-fold higher than the 
secondary only control (24 ± 6 versus 10 ± 3).  
Flow cytometry analysis of permeabilised cells revealed a greater extent non-specific 
binding of the secondary antibody in both cell lines, compared to non-permeabilised cells 
(compare Figure 3.1C and D). However, this increased “background” staining was 
accompanied by an increase in specific GRP-R staining in both cell lines. In H345 cells the 
total cellular expression increased to 130. A549 cells displayed the greatest expression with 
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an MFI of 318. The sum of the surface and total expression MFI for A549 cells is 
significantly greater (P < 0.05) than H345 cell line. 
 
 Figure 3.1: GRP-R expression data in H345 and A549 cells. A & B: Forward scatter (FS) 
and side scatter (SS) flow cytometry profiles of control non-permeabilized A549 and NCI-
H345 cells, respectively. Gates are shown in the dotted lines. C & D: Median FL-1 
fluorescence intensity (MFI) of non-permeabilised (C) and permeabilised (D) H345 and 
A549 cells.  Data shown in C are from two separate experiments. Data in D are from a single 
experiment due to limited antibody availability. 
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3.3.2 Peptide synthesis 
Early studies involved synthesis of an N-terminal cysteine mutant of the agonist bombesin 
peptide including residues 6-14 (Cys-Gln-Trp-Ala-Val-Gly-His-Lue-Met-NH2) after which 
the project moved towards the use of an unnatural antagonist peptide, Cystabn (Cys-D-Phe-
Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2). 
3.3.2.1 Cys-bombesin (6-14) 
Cys-bombesin (6-14) synthesis was performed using manual Fmoc SPPS using standard 
double coupling approach with a good crude yield of 78 %.   HPLC analysis of crude peptide 
revealed a retention time (RT) of the peptide was 14.0 minutes and a purity of 85% (Figure 
3.2A).  MALDI ToF MS analysis confirmed the presence of the intact peptide. The mass 
spectrum shown in Figure 3.2B included [M+H] + = 1043.1 Da, [M+Na] + = 1065.1 Da,  
[M+K]+ = 1081.1 Da.  UV-Vis spectroscopic analysis of the peptide included absorbance 
bands at 280 nm (Figure 3.2C) corresponding to the tryptophan indole side chain (Figure 
3.2D).
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Figure 3.2: Characterisation of Cys-bombesin(6-14). (A) RP-HPLC chromatogram, (B) MALDI ToF MS spectrum and (C) UV absorbance 
spectrum of crude Cys-bombesin (6-14). Panel B show the correct masses of peptide. Mass data [M+Na] + (calculated) = 1065.48 Da, [M+Na]+ 
(observed) = 1065.1 Da, [M+H]+ = 1043.1 Da, [M+K]+ = 1081.1 Da). D: structural formula of Cys-bombesin(6-14) along with the 
corresponding three letter amino acid annotation.
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3.3.2.2 Cystabn 
The antagonist peptide, Cystabn was synthesized by manual Fmoc SPPS with a good yield 
of 92 % post-cleavage. RP-HPLC analysis using a 30 minute gradient program (Figure 3.3a) 
revealed number of unresolved peaks. Peak integration of the largest peak (RT = 14.5 min.) 
estimated the yield to be ~55%.  Figure 3.3a shows the MALDI ToF mass spectrum of crude 
Cystabn (Exact mass = 1215.62 Da). The mass spectrum includes: [M+Na]+ = 1238.3 Da as 
the predominant ion (calculated [M+Na]+ = 1238.62 Da), [M+H]+ = 1216.3 Da. The UV 
absorbance (Figure 3.3C) corresponds mainly to tryptophan shown in the peptide sequence 
(Figure 3.3D).
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Figure 3.3: Characterisation of Cystabn peptide. RP-HPLC chromatogram (A), MALDI ToF MS spectrum (B) and UV absorbance spectrum 
(C) of crude Cystabn. Panel B show the correct masses of peptide. Mass data [M+Na]+ (calculated) = 1238.62 Da, [M+Na]+ (observed) = 
1038.3 Da, [M+H]+ = 1216.3 Da) D: structural formula of  Cystabn along with the corresponding three letter amino acid annotation. Sta = 
gamma amino acid, statine.
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3.3.2.3 Scrambled Cystabn peptide 
Scrambled cystabn was synthesized by manual Fmoc SPPS with a good yield of 94 %. HPLC 
analysis showed crude peptide purity to be 70% with a RT of 14.8 minutes (Figure 3.4A). 
Scrambled cystabn was analysed with MALDI ToF MS (Figure 3.4B) to confirm the mass 
of the peptide (Exact mass = 1215.62 Da). The spectrum showed [M+Na]+ (observed) = 
1238.3 Da high, (calculated [M+Na]+ = 1238.62 Da), [M] = 1215.4 Da. The UV absorbance 
spectrum (Figure 3.4C) includes the expected absorbance bands at 280nm corresponding to 
the tryptophan indole ring expected from the peptide primary sequence (Figure 3.4D).
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Figure 3.4: Characterisation of scrambled Cystabn peptide. RP-HPLC chromatogram (A), MALDI ToF MS spectrum (B) and UV absorbance 
spectrum (C) of crude scrambled Cystabn. Panel B show the correct masses of peptide. Mass data [M+Na]+ (calculated) = 1238.62 Da, 
[M+Na]+ (observed) = 1038.3 Da, [M]+ = 1215.4 Da). D: structural formula of Cystabn along with the corresponding three letter amino acid 
annotation. Sta = gamma amino acid, statine.
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3.3.3 Conjugate synthesis (DSPE-PEG2000-cystabn) 
The DSPE-PEG2000-Cystabn conjugate was synthesised using thiol–maleimide 
conjugation reaction with a good yield of 98 % (scheme 3.1). After purification by dialysis, 
the conjugate was characterized by HPLC on a C8 column to afford analysis of the less polar 
conjugate (Figure 3.5A). Purity of the peptide was determined to be 86% upon peak 
integration. The retention time (RT) of the peptide was 18.94 min. The conjugate was 
analysed with MALDI ToF MS to confirm the mass of the conjugate (Figure 3.5B). The 
exact mass of the DSPE-PEG2000 maleimide was calculated as 4137.41 Da but is unreliable 
due to the polydisperse nature of the PEG linker. The mass spectrum include the most 
abundant ion at 4188 Da. The expected mass difference between ion peaks is 44 Da, which 
represents ethylene glycol monomers (C2H4O = 44.05). Figure 3.5b includes, for example, a 
mass difference from 4277.57 Da to 4321.49 Da, which is equal to one monomer. Two 
monomer mass differences of ~ 88 Da (4100.68 Da to 4188.41 Da) equivalent to two 
ethylene glycol monomers were also recorded.  
The conjugate also, characterized by UV spectrometer. The conjugate dissolved in 
chloroform and analysed over the UV range of 200 nm to 400 nm. At 280 nm, the observed 
absorbance (Figure 3.5C) corresponds mainly to tryptophan shown in the conjugate structure 
(Figure 3.5D). The noisy background lower than ~ 250 nm is attributable to the interference 
presented by solvent contaminants. 
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Scheme 3.1:  Synthesis of the DSPE-PEG2000-cystabn. Thiol–maleimide conjugation 
reaction between one equivalent of DSPE-PEG2000-maleimide (a) and two equivalents of 
cystabn (b) to give DSPE-PEG2000-cystabn (c).
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Figure 3.5: Characterisation of DSPE-PEG2000-cystabn conjugate. RP-HPLC chromatogram (A), MALDI ToF MS spectrum (B) and UV 
absorbance spectrum (C) of the crude conjugate. Panel B show the masses spectra of the conjugate spread around (4137.41 Da calculated, 
which is the mass of the conjugate) with 44.05 Da peak separation. This 44.05 difference in masses between peaks equal to one ethylene glycol 
monomer. Blue and red arrows indicate peak separation by one or two glycol monomers, respectively. D: structural formula representation of 
DSPE-PEG2000-cystabn conjugate. N.B. the exact structure of the PEG chain is unknown.
Chapter 3 
 
 
95 | P a g e  
 
3.3.4 Formulation of the targeted and control liposomes 
The thin film hydration protocol used to prepare liposomes produced reproducible 
monodispersed SUVs. The mean diameters for both liposomal were 101± 2.1 nm and 101± 
2.3 nm for control and targeted liposomes, respectively. The polydispersity index is < 0.1 
for both formulations indicating monodispersed population (0.058 ± 0.007 and 0.068 ± 0.019 
for control and targeted liposomes, respectively). The zeta potential of both formulations 
were slightly negative i.e. -1.64 ± 2.13 mV and -1.86 ± 1.64 mV for control and targeted 
liposomes, respectively. Representative size and zeta potential measurements are 
summarized in Table 3.2. 
Figure 3.6a and 3.6c shows the DLS autocorrelation function data for both formulations 
(control and targeted formulations respectively). Both correlation curves produced show 
smooth single exponential decay function, which indicates mono-disperse particle 
suspensions. Cumulants analysis used to extract the Z-average and polydispersity index from 
the curve. Figure 3.6b and 3.6d shows the intensity weighted size distribution with good 
reproducibility for both formulations (control and targeted formulations respectively).    
Freshly prepared control and targeted liposomes showed consistent (p>0.05) size, zeta 
potential and polydispersity measurements. A Z-average diameter of 101 nm and a zeta 
potential of -1.6 mV with a narrow polydispersity index of 0.06 indicating a refined 
unilamellar formulation for the control formulation. Similarly, the targeted formulation 
showed size, zeta potential and polydispersity measurement of 100 nm, -1.9 mV and 0.07, 
respectively. 
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Figure 3.6: DLS characterisation of control and cystabn-targeted liposomes. 
Autocorrelation functions (A & C) and intensity weighted size distribution date for (B & D) 
of control liposomes (top row) and targeted liposomes (lower row). Each panel shows results 
from three independent experiments in red, green and blue. 
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Table 3.6 : Summary of liposomes physical characteristics 
 Control liposomes Cystabn-targeted liposomes 
Z-Ave (d.nm) 1 101 ± 2.1 100 ± 2.3 
PDI 2 0.058 ± 0.007 0.068 ± 0.019 
ZP (mV) 3 -1.64 ± 2.13 -1.86 ± 1.64 
Data shown are mean ± SD, n=3 independent experiments. 
1 Z-averaged hydrodynamic diameters (Z-Ave) obtained by cumulant analysis of the auto-
correlation functions. 
2 Polydispersity indexes (PDI) obtained by cumulant analysis of the auto-correlation functions. 
3 Zeta potential (ZP) was measured in PBS with 137 mM NaCl.  
 
3.3.5 Liposome physical stability study 
The colloidal stability of liposomes is an important factor for in vitro and in vivo application 
of liposomes. The physical stability of targeted and control liposomes was studied in PBS 
and 10% serum over three days. The physical stability of the liposomes in PBS monitored 
using the size and the zeta potential over the period of the study whereas only the size 
parameter used to monitor the physical stability of the liposomes in 10% serum.  
Both liposomal formulations showed a good stability in PBS along the storage period 
reflected by their size (Figure 3.7A-B) and zeta potential (Table 3.7). Compared to the 
respective freshly prepared formulations, there no significant change (p>0.05) in the size, 
polydispersity and zeta potential of either liposomal formulations upon storage in PBS for 
the whole storage period at the three different temperatures i.e. 4 °C, 25 °C and 37 °C. The 
largest change recorded for the control formulation from 0.058 ± 0.007 to 0.098 ± 0.07 PDI 
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after incubation at 25 °C for 72 h. In general, the PDI for the targeted formulation increased 
greater than that of control liposomes. For example, the PDI rose from 3-fold from 0.068 ± 
0.019 to 0.176 ± 0.08 after 72 h incubation at 25 °C.  There were no significant changes in 
zeta potential (p>0.05) for both formulations. For the control formulation, the zeta potential 
decreased from -1.64 ± 1.42 to -2.57 ± 1.15 mV after incubation at 25 °C for 24 h. For the 
targeted formulation, the zeta potential decreased from -1.76 ± 0.56 to -3.55 ± 1.96 mV after 
incubation at 37 °C for 72 h. 
As expected, storage of liposomes in 10% FBS caused more physical instability than storage 
in PBS (Figure 3.8 cf. Figure 3.7). There was non-significant change in the parameters of 
the control and targeted formulations (p>0.05) immediately after addition of 10% FBS. For 
the freshly prepared control formulation, the size slightly decreased from 93.93 ± 1.78 to 
89.79 ± 1.52 nm with slight increase in PDI from 0.083 ± 0.002 to 0.160 ± 0.012 immediately 
after addition of 10% FBS. For the freshly prepared targeted formulation, the size slightly 
increased from 105.5 ± 3.42 to 113.37 ± 20.51 nm with slight decrease in PDI from 0.055 ± 
0.019 to 0.241 ± 0.148 immediately after addition of 10% FBS. However, the targeted 
formulation (figure 3.8b) showed trending instabilities reflected by its polydispersity values 
proportional to the storage temperature and duration. For example, storage of targeted 
liposomes at 37 °C after 72 hours showed the highest PDI (0.7, p<0.05) compared to the 
freshly prepared sample (PDI=0.068 ± 0.019).  After storage for 72 hours, the PDI of the 
targeted formulation increased greatly from 0.19 at 4 °C to 0.56 at 25 °C to 0.70 at 37 °C 
(p<0.05). This indicates that the colloidal stability decreases with storage duration and 
temperature. Storage at 37 °C in 10% FBS caused the most instability regardless of duration. 
It is also noted that, no increases in size or PDI (p>0.05) were seen when targeted liposomes 
were stored in 10% FBS at 4 °C. 
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Figure 3.7: Physical stability in PBS: (A) and (B) are the Z- average and PDI data for the 
control and targeted liposomes respectively. Mean ± SD, n=3. 
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Table 3.7: Zeta Potential for the control and targeted liposomes 
Control liposomes 
Time (h) 0 24 72 
Temperature 
(°C) 
RT 4 25 37 4 25 37 
ZP (mV)1 
-1.64 
±1.42 
-2.59 
±0.95 
-2.57 
±1.15 
-1.50 
±0.80 
-1.28 
±0.87 
-1.57 
±0.91 
-1.66  
±0.72 
Targeted liposomes 
Time (h) 0 24 72 
Temperature 
(°C) 
RT 4 25 37 4 25 37 
ZP (mV)1 
-1.76 
±0.56 
-1.40 
±0.56 
-2.12 
±0.69 
-3.76 
±1.11 
-2.73 
±1.15 
-1.65 
±0.54 
-3.55 
±1.96 
Data shown are mean ± SD 
1 Zeta potential (ZP) was measured in PBS with 137 mM NaCl. 
          
  
Chapter 3 
 
 
101 | P a g e  
 
 
Figure 3.8: Physical stability of liposomes in 10% serum: (A) and (B) are the Z- average 
and PDI data (n=3) for the control and targeted liposomes respectively. 
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 Discussion  
In order to work towards a targeted liposomal formulation or SCLC it is necessary to identify 
an appropriate targeting strategy such that liposomes can be appropriately enriched at the 
target site. Here, the GRP-R was targeted in light of the growing evidence for the role of 
bombesin-related peptides and their cognate receptors (e.g. GRP-R) in cancer biology and 
targeting. 
To examine for differences in the GRP-R expression levels in the two lung cancer cells lines 
(one SCLC and one NSCLC) an indirect antibody labelling was performed followed by 
semi-quantitative detection by flow cytometry. The relative amount of GRP-R expressed on 
the cell surface of non-permeabilised cells was >2-fold greater in H345 cells than A549 cells 
indicating a wider availability of the target on this cell type.  Intriguingly, analysis of 
permeabilised cells revealed that A549 cells express a greater total amount of GRP-R 
compared to H345. This result was however accompanied by a greater amount of 
background non-specific binding of the secondary antibody in both cell lines, compared to 
non-permeabilized cells. This observation of increased cell surface expression does support 
the rationale for targeting GRP-R on this cell type in spite of evidence to suggest a sub-
optimal antibody labelling protocol for potentially both primary and secondary antibodies.  
The antibody clone used in this study was raised against the second extracellular loop of the 
GRP-R and therefore affords the detection of both surface expressed and intracellular 
protein. It is not possible to state conclusively whether the antibody recognises optimally its 
antigen in the intracellular environment where there is potential for receptor folding or 
conformational distortion that might lead to weak binding and /or non-specific binding to 
other bombesin receptor family members. Due to the limited availability of the GRP-R 
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antibody it was impossible to properly optimise the antibody labelling technique. An 
optimised protocol would afford the titration of both primary and secondary antibody 
solution for the studyof GRP-R expression in a wider range of SCLC, NSCLC and normal 
lung epithelial cell lines. 
As summarised in the introduction there are various and sometimes contradictory data in the 
published literature regarding the expression of GRP-R mRNA and protein in lung cancer 
models and patient tissues Moreover, the growth of NSCLC tumours in mice was suppressed 
by more than 30% using GRP-R antagonist [32]. Although the A549 cell line was not 
intended to serve a GRP-R negative cell line in this study it would be appropriate in future 
studies to incorporate normal human lung epithelial lines as a control to appropriately 
measure the targeting indices if GRP-R targeted liposomes. 
The development of a targeted liposomal drug platform relies on the use of an appropriately 
specific targeting moiety. In this work an antagonist peptide was used as a high affinity 
targeting ligand for GRP-R in place of the widely used bombesin (6-14) peptide which has 
been shown to impart an autocrine growth effect on SCLC lines. Fmoc-SPSS was used to 
prepare C’ terminal amidated peptides on a small scale of ~50-100mg. Initial work on the 
synthesis of Cys-bombesin (6-14) delivered a product in good yield, however HPLC analysis 
indicated the presence of a closely related structural impurity account for >40% of the 
product. It would be expected that the contaminant would be a truncated or otherwise 
modified peptide from the synthetic procedure. Surprisingly, MALDI-TOF analysis revealed 
no such truncated or related peptides and the UV absorbance spectrum indicated the presence 
of a native tryptophan without the presence of an oxidise tryptophan that would present an 
altered UV absorbance spectrum in addition to distinct HPLC peaks and MALDI-TOF 
peaks. Similar levels of impurities were observed in HPLC analyses of the Cystabn and 
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scrambled cystabn peptides. Nonetheless, confirmatory UV and MALDI-TOF data 
supported the use of these crude peptides without further purification. Indeed, conjugation 
of the Cystabn peptide to DSPE-PEG-maleimide proceeded successfully to yield a peptide-
PEG-lipid conjugate with a mass around 4.5kDa. Significant method development was 
required to establish the reaction solvent conditions that encouraged reactant and product 
solubility while maintaining reaction efficiency in addition to the choice of purification 
method. The choice of dialysis as a purification method is favourable to HPLC which has 
the drawback of sample losses on repeated injection as well as time consuming testing of 
column fractions and solvent evaporation to recover the product.  
MALDI-TOF MS was chosen as the definitive analytical technique of choice for proving 
successful peptide-PEG-lipid conjugation. However, initial attempts were unsuccessful due 
to inefficient sample ionisation and a predominance of matrix-associated ions at low m/z. 
The technique was optimised through iterative trialling of MALDI matrices (e.g. -
cyanohydroxycinnamic acid, DHB, dithranol) as well as a number of sample mixing or 
layering techniques such as mixing, layering, sandwiching.  Mass spectra with good 
resolution were achieved following optimal mixing of a high sample concentration with a 
mixture of matrices in a layer on layer approach. Successful conjugation was concluded 
when regions of the mass spectrum, centred around the expected product mass range, 
included the signature pattern of 44 Da peak spacing consistent with a PEG polymer. 
Moreover, reaction completion was indicated by the absence of peaks in the mass range 
occupied by the DSPE-PEG-maleimide. 
Time constraints prohibited the synthesis of the scrambled Cystabn-PEG-lipid conjugate 
although the product was tested in cell growth assays (Chapter 4). In place of a control 
liposome presenting the scrambled Cystabn peptide a control liposome formulation was 
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prepared in which 5% total DOPE-PEG was included rather than 4% DOPE-PEG + 1% 
cystabn-PEG-DSPE. The use of this as a control was sub-optimal as judged by the lower 
colloidal stability of the peptide-loaded formulation compared to the bare control liposome. 
The observed increases in PDI and particle size over the 72 h time period could result from 
interference by the displayed peptide on the liposomal surface charge. Alternatively, the 
presence of protease substrates on the vesicle surface might also have attracted enzymes that 
indirectly destabilise the liposome through surface charge modification. It should be noted 
however the times scale for peptidase/protease instability are likely to be considerably 
shorter than the first 24 hour timepoint.  This increase in size probably caused by 
opsonisation process.  Opsonization of liposomes by plasma proteins plays a critical role in 
the clearance of injected liposomes in vivo. Upon exposure to serum or plasma, liposomes 
rapidly adsorb a vast collection of protein molecules, as demonstrated by isolation of 
liposomes from in vitro incubations with serum/plasma [144, 145]. Szebeni et al. 
demonstrated that using DSPE-PEG2000 in the liposomal formulation (HSPC/Chol), with 
same size and lipid composition as Doxil®, promoted complement activation and 
opsonisation in human serum in vitro, compared to HSPC/Chol as control [146]. Key 
information on particle stability in physiological fluids could be extracted from zeta potential 
measurements although it is extremely difficult to monitor the zeta potential in 10% serum 
as it presents a diverse collection of proteins which may bind in dynamic equilibrium with 
the liposome and affect greatly the accuracy of the zeta potential measurement.  
Initial work involved a successful synthesis of Cys-bombesin (6-14) however it was 
abandoned at an early stage of the project in order to focus on an antagonistic peptide 
sequence. Chandra et al [147] used bombesin (6-14), without the N terminal cysteine 
residue) a targeting ligand for the delivery of starch-stabilised gold nanoparticles to PC-3 
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prostate cancer cells in vitro. In vivo studies indicate that their functionalised nanoparticles 
are able to target the GRP receptor-enriched pancreatic tissue such that ~45% of the injected 
dose of 198Au-labelled particles were recovered from the pancreas. Nonetheless, it was 
decided that a more rational alternative would involve the deployment of an antagonistic 
peptide (Cystabn) that does not carry the risk of a mitogenic effect on target cells. However, 
antagonistic peptide as will be shown in the next chapter, will not stimulate cell growth. 
There is a study which also suggest that using antagonistic peptide for Bombesin may be 
preferable in cancer targeting over agonist due to higher tumour uptake and longer tumour 
washout [148]. Others have developed GRP-like peptides with antagonist activity at their 
receptor. One such peptide, [D-Phe6, Sta13, Leu14] Bombesin(6-14), shows high affinity 
binding to GRP-R (IC50 = 2.2 nM by competitive binding method) and stimulates receptor 
internalisation. A structurally related peptide, KJGJKG displayed a higher binding affinity 
(IC50 0.5 nM by competitive binding method) but includes a complex Psi amino acid that is 
synthetically challenging to prepare [49, 149].  In this project, the [D-Phe6, Sta13, Leu14] 
Bombesin(6-14) sequence was chosen as a compromise between high affinity antagonist 
activity with ease of peptide synthesis.  
This pepide-PEG-lipid conjugate was subsequently used to prepare unilamellar liposomes 
in which the extent of loading of targeting conjugate was 1% of the total 5 % mol of pegyated 
lipid.  The characterization of the liposomes showed a monodisperse liposome suspension 
with a slightly negative zeta potential (-1.64 for control and -1.76 for targeted liposomes in 
PBS). The value of zeta potential is closer to zero because the formulations contain the 
zwitterionic phospholipid (DOPC). The colloidal and biological stability of the system is 
provided through the steric hindrance effect caused by pegylation. Pegylation achieved by 
inclusion of 5 mole % DOPC-PEG2000. The pegylation of the surface of liposomes in the 
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range of 5-10 mole % using PEG2000-lipid found to provide the longest circulation time in 
vivo [150, 151]. At this range, a dense polymer brush formed at the surface and yielding the 
repulsive steric interaction For anticancer application, the optimal size of < 200 nm provide 
highest tumour retention by utilizing Enhanced Permeability and Retention (EPR) of the 
tumour. Most current approved anticancer nanomedicines have sizes range from 100-200 
nm. However, size range of < 20 nm will cause removal of nanoparticles by renal clearance 
and fenestrated capillaries. In addition to that, as the size increase >150 nm, the accumulation 
in the spleen, liver and bone marrow enhanced [152]. The mean size of the liposomes were 
about 100 nm even though they were extruded finally though a 50 nm filter. To further 
enhance the tumour accumulation, targeting moiety were incorporated as 1 mole % DSPE-
PEG2000-maleimid. By using this approach, cystabn will be available unhindered to identify 
and bind to its receptor on the cancer cell [75, 153].  
Liposomes are limited by their physical instability caused by aggregation or fusion of 
vesicles to form larger particles [154]. This can affect both in vitro and in vivo liposomal 
behaviour. The stability of a colloidal system is determined by the balance of attractive and 
repulsive forces between suspended particles in the medium. An increased repulsive 
contribution increases the colloidal stability. Increased steric repulsion by particle pegylation 
is one type of the approaches that is commonly used to provide liposomal stability. This type 
of stabilization provides increased colloidal stability for slightly charged nanoparticles. In 
addition to that, it provides in vivo stability by preventing rapid clearance by the immune 
system [155]. Although the exact mechanism for pegylation induced stability is not 
understood, the hypothesized mechanism by which steric stabilization work is preventing 
electrostatic, hydrophobic and van der waals interactions [156]. 
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  Conclusion  
In this chapter we confirmed GRP-R to be overexpressed on the surface of the SCLC cells 
(H345), which justifies targeting SCLC cells by targeting the receptor for delivery of drugs. 
The receptor shown to be expressed in both cell lines (H345 and A549) with >2 fold 
increased surface expression in SCLC cells. Cys-bombesin(6-14), cystabn and scrambled 
cystabn were successfully synthesised using the Fmoc SPPS method. This confirmed using 
MALDI-ToF MS and the UV data. In addition to that, conjugation with DSPE-PEG2000-Mal 
was evidently successful.  Targeted and control liposomes were synthesised and tested for 
their stability in aqueous media. The data revealed monodispersed formulation with size of 
about 100 nm for both formulation. Good stability demonstrated in PBS for both formulation 
whereas time-dependant instability in 10% FBS.  
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 Introduction 
Liposomes have several advantages as drug carriers including biocompatibility, 
biodegradability and a capacity to entrap hydrophilic and lipophilic molecules within their 
aqueous core and bilayer respectively. Conventional liposomes have been shown to be 
rapidly eliminated from the bloodstream by mononuclear phagocyte system. Further 
development of these vesicles led to the use of polymers (mainly PEG) to be grafted onto 
liposomal surface. This improves the passive targeting of liposomes to malignant tissue 
through the enhanced permeability and retention (EPR) effect. To achieve active targeting 
to cancer cells the liposome surface can also be modified with specific targeting moieties 
such as antibodies, sugars, peptides to further refine biodistribution to target tissue and to 
improve drug pharmacokinetics. One of the most important aspect of liposomal drug 
formulation is its cellular uptake in the target tissue of interest such that the extent of drug 
accumulation in the tumour can be predicted when delivered in vivo. 
In this chapter, the cellular uptake of fluorescently labelled Cystabn-targeted liposomes was 
determined in the A549 and NCI-H345 cell lines by flow cytometry. Liposomes prepared 
without the Cystan-targeting peptide were used as control to determine the specificity of 
peptide-targeting to the GRP receptor. 
The aims of this chapter were to: 
1) Evaluate the targeting moiety mitogenicity to SCLC cells (H345)  
2) Study the targeted liposomal uptake in SCLC cells  
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 Materials & methods 
4.2.1 Materials 
All materials were of analytical grade and sourced from either Sigma or Fisher unless 
mentioned otherwise. 
4.2.2 Cell Culture 
All cell cultures were maintained at 37 °C, 5 % CO2, and 95 % air in a humidified incubator 
and routinely passaged at confluency. Further details are found in Chapter 3. 
4.2.3 MTS proliferation assay with bombesin-derived peptides 
The A549 and H345 cell lines were seeded in 96 well plates at 5000 cells/well. Cystabn and 
its scrambled form were serially diluted 4-fold from 742.4 nM to 11 pM. Both cell lines were 
incubated with the peptides in complete medium containing 2% FBS for various time points. 
For A549 cells, the doubling time is 22 h, so the cells treated with reagent at 24 h, 48 h and 
72 h. In contrast, H345 cell doubling time is 122 h, so the treatment performed at 5 days, 7 
days and 10 days. At each time point 10 μL MTS/PES reagent was added per 100 μL (stock 
concentration of 2 mg/mL MTS and 0.92 mg/mL PES) to the A549 and H345 cells and were 
incubated at 37 °C for 4 hours and 6 hours respectively. The absorbance at 492 nm was 
measured using BMG LABTECH FLUOstar OPTIMA Microplate Reader. The positive 
control was 1% Triton X-100 and the negative control was 2% FBS medium without 
peptides. 
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4.2.4 Liposomes uptake experiment by flow cytometer using fluorescent probe 
The Cystabn-targeted fluorescent liposomes and control florescent liposomes (both 
including 1 mole % DHPE-fluorescein) were prepared by thin film hydration method as 
described in the Chapter 2/3. The two formulation characterized in terms of their size and 
surface charge using Zetasizer Nano ZS.  
To perform uptake experiments the H345 cell line was subcultured into 12 well plates as 
described in chapter 3 and incubated overnight. The cell media was removed by 
centrifugation (200 g, 5 min) and replenished with serum-free DMEM and incubated at 37 
°C and 4 °C (as control). The stock fluorescent liposome solution (10 mg/mL lipid) was 
diluted 1:13 in serum-free medium such that the final lipid concentration was 0.769 mg/mL 
and a final targeting peptide concentration was 38 μg/mL (31.24 nM). These conditions were 
chosen according to the published literature [157, 158] as those suitable for generating a 
measurable fluorescence response for flow cytometry. Cells were incubated at 37 °C or 4 °C 
for 15-120 min before transfer to ice to stop liposome internalisation. Cells were transferred 
into microfuge tubes and washed with PBS (x3), then cells were resuspended in PBS. Flow 
cytometry analysis was performed using a Beckman Coulter Cytomics FC500 flow 
cytometer equipped with a 15 mW argon-ion laser. Cells were analysed on the basis of 
forward light scatter (FS), side light scatter (SS) and DHPE- fluorescein fluorescence 
(excitation/emission maxima ~496/519 nm) by FL-1 detector. Typically, fluorescence 
information for 10000 events was collected for each sample using Kaluza Analysis Software. 
Data were analysed by gating live cells, as judged by FS versus SS dot plots, and plotting 
the fluorescence of these cells in a histogram. Fluorescence profiles or histograms shown 
were representative of those obtained from the number of experiments indicated. The 
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increase in fluorescence intensity above background was determined by measuring the shift 
in fluorescence intensity from peak to peak, relative to the indicated control. 
 Results 
4.3.1 Mitogenicity of cystabn  
The effect of cystabn peptide on the proliferation of both cell lines was determined by MTS 
assay. Both cell lines were treated with a dose-range of cystabn and scrambled cystabn 
control across the concentration range ~750 nM to 11.5 pM. For the slow dividing H345 cell 
line the effect of peptides was determined over 5, 7 and 10 days (Figure 4.1). There was no 
observed increase or decrease in absorbance across the tested concentration range of either 
peptide at any of the time points. The low absorbance values measured in Figure 4.1 a-c 
were recorded after an extended incubation time with the MTS reagent and indicate a low 
metabolic capacity of this cell line. Absorbance values measured for the 1% Triton control, 
was 0.33 AU for A549 cells and 0.2 AU for H345 cells.  
In A549 cells (Figures 4.1 d-f) the Cystabn and scrambled peptide antagonists had no 
measurable effect on proliferation and there was no significant difference (P > 0.05) in the 
absorbance values across time points. The consistenecy of absorbance values at the lowest 
peptide concentrations reflects the fast growing nature of A549 cells and the rapid 
achievement of 85-100% confluency by 24 hours and beyond.  
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Figure 4.1: MTS cell proliferation assays. Viability of cells was measured at 492 nm for 
H345 cells at 5 days (A), 7 days (B) and 10 days (C); and for A549 cells at 24 h (D), 48 h 
(E) and 72 h (F). prior to measurement, H345 and A549 cells were incubated with MTS/PES 
reagent for 6 hours and 4 hours respectively. Error bars show standard error of the mean 
(n=3 independent experiments). 
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4.3.2 Uptake of targeted liposomes 
Flow cytometry was used to evaluate the uptake, into A549 and H345 cells, of targeted and 
control liposomes (without the targeting moiety) labelled with 1 mole % DHPE-fluorescein. 
Due to time constraints these studies were performed only in H345 cells. H345 has higher 
surface GRP-R expression as discussed in Chapter 3 and it is the cell line of interest in this 
study.  
The liposomes were incubated with H345 cells for 15 - 120 minutes at 37 °C and for 120 
minutes at 4 °C (as no-uptake control). The cell suspensions presented a homogenous 
dispersion and cells were gated based on FS/SS of the control cells (i.e. without treatment) 
as shown in example scatter plot Figure 4.3A and fluorescence histogram of the gated 
population (Figure 4.2B). It is apparent from Figure 4.2 B that the control population showed 
negligible background fluorescence. Figures 4.2C and 4.2D show the fluorescence 
histogram of the gated populations of H345 cells for control and targeted liposomes 
respectively. The shift in the florescence intensity of samples from three independent 
experiments are shown in Figure 4.2E. 
From Figure 4.2C it is apparent that cells incubated at 4°C with fluorescently labelled control 
liposomes marginally higher MFI than untreated control cells (1.6 and 2.5 for control and 
targeted liposomes respectively). For the control formulation experiment shown in Figure 
4.2c there was a marginal rightward shift in the FL-1 intensity upon increased incubation 
time indicating an increased uptake of fluorescent liposomes. Calculation of the median 
fluorescence intensity (MFI) of each histogram from there independent experiments 
indicated that there was no increase in the FL1 intensity over the 120 min.. For example, the 
MFI decreased from 4.24 ± 0.8 at 15 min to 3.76 ± 0.02 at 120 min.  
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Over the time course of the experiment there was a small increase in the MFI for H345 cells 
incubated with the targeted formulation (Figure 4.2D). There was an observable shift in the 
florescent signal of all time points at 37 °C compared to the florescent signal of 120 minutes 
at 4 °C. This indicate that liposomes are internalised by H345 cells but to a limited extent. 
However, there are no significant difference between time points of the same formulation at 
37 °C as well as between formulations (p > 0.05). however, there is a slight increase in the 
uptake of the targeted formulation at 60 °C compared to the control formulation (4.58 ± 0.77 
and 3.32 ± 0.24 respectively). 
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Figure 4.2: Flow cytometry analysis of liposomes uptake by H345 cells. (A) example of cell 
gating strategy dot plot for H345 control cells (without treatment). FS: Forward scattering, 
SS: side scattering. (B) FL-1 fluorescence histogram shift of the control sample. The bar 
labelled C indicates the exterior of the gate in which increased FL-1 fluorescence was 
detected. (C) and (D) show the FL-1 histograms of control formulations (CF) and targeted 
formulations (TF) after incubation with H345 cell line for 120, 60, 30 and 15 minutes at 37 
°C and for 120 minutes only at 4 °C (as control). Cell suspensions were analysed with a 
Cytomics FC500 flow cytometer. The median florescence intensities (MFI) represented for 
both formulations at 37 °C. Error bars show standard error of the mean (n=3 independent 
experiments).  
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 Discussion  
Active targeting of nanomedicines to cancer cells is a challenging concept to achieve. In the 
case of SCLC targeting we sought in this work to exploit bombesin-derived peptides in order 
to target the cognate GRP receptor that is reported to be upregulated in SCLC cells. We 
hypothesised that the use of a N-terminal cysteine derived GRP receptor antagonist peptide 
(Cystabn) avoids the mitogenic effect of bombesin peptides that might compromise this 
targeting approach by causing agonist-induced GRP receptor activation and stimulation of 
cancer growth [4, 27].  
The effect of Cystabn peptide on the proliferation of two GRP-R positive cell lines (A549 
and H345) was evaluated by MTS assay after incubation with a dose-range of cystabn and 
scrambled cystabn control peptide. There was no change in the absorbance of either cell 
cultures caused by either peptide indicating the absence of a pro-mitogenic response. These 
experiments were designed such that any increase in cell proliferation would be registered 
as an increase in MTS absorbance. In the case of A549 cells (doubling time 22 h) the MTS 
absorbance was high at each of the timepoints of indicating high confluency even at 24 hours. 
Visual inspection of the A549 cell monolayers confirmed the confluency to be <100% so 
further studies would be required in order to optimise the seeding density and peptide 
treatment times. In contrast, the slow-growing H345 cells (doubling time, 122 h) displayed 
very low MTS absorbance levels that were comparable to the 1% Triton X-100 control at 5, 
7 and 10 days post-treatment. The 10 day exposure for H345 cells was designed to include 
two population doubling times and this sub-optimal result warrants further investigation. 
The reduction of serum concentration from 10% to 2% would have a direct negative effect 
on the cellular proliferation rate but also reduces the exposure to serum-derived mitogenic 
factors that drive cell proliferation in faster growing cells such as A549. In summary, the 
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absence of a pro-proliferative activity of Cystabn justifies its use as a targeting ligand as 
opposed to the agonist peptides which have been shown to promote cell proliferation of 
SCLC cells in vitro (using NCI-N592 cells). In the work of Cuttitta et al [42] an anti-GRP 
antibody (2A11) supressed SCLC xenograft growth in mice by 50% in mass compared to 
the control group. Distinct from GRP and bombesin-related peptides other small 
proteins/peptideshave been shown to act as growth factors in malignancies such as bladder 
[159] and prostate [160] cancer. For example, vascular endothelial growth factor (VEGF), 
acts as angiogenetic factor in several tumours and the use of an anti-VEGF receptor 3 
antibody (mF4-31C1), the growth of several tumours such as prostate cancer in mice have 
been suppressed [160].   
With evidence of cell surface expression of GRP receptor and the absence of mitogenic 
effects associated with Cystabn treatment targeted liposomes were prepared. Specific 
binding of targeted liposomes to their target site is an important factor in optimising the 
targeted delivery to cancer cells. In this study, we have performed semi-quantitative analysis 
of the internalization of cystabn targeted fluorescent liposomes to H345 cells in comparison 
to control. In general, the extent of liposome internalisation was low, as evidenced by a 
marginal increase in the FL-1 detector signal over the 120 min time course. More 
significantly, for both control and targeted formulation there were no significant differences 
in cellular MFI between time points. There was a noticeable increase in the MFI between 
control cells incubated at 4 °C and those incubated at 37 °C. These largely inconclusive data 
demand further investigation into the reasons for low cellular uptake. The studies presented 
here were performed on freshly cultured cells and which would be expected to have a typical 
endocytic internalisation rate that would be measured as a time-dependent increase in MFI 
over a 2 hour time period as reported for other probes [161, 162]. 
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To achieve effective drug delivery, internalization into the cell is required because most anti-
cancer drugs act on intracellular targets. There are generally three possible mechanisms of 
liposome cargo delivery into target cells. Firstly, upon binding to their cell surface bound 
target liposomes can release their contents in the extracellular region of the target cells. This 
increases the local drug concentration which drives passive uptake into the cell. The major 
challenge to the exploitation of this mechanism is to ensure selective extracellular drug 
release. Secondly, liposomes can fuse with the cell membrane and release their contents 
intracellularly. An example of this is using diplasmenylcholine to formulate plasma-stable 
liposome which release its content intracellularly at endosomal pHs [163]. Thirdly, cell-
bound liposomes can be internalised by the target cells via receptor-mediated endocytosis 
and release their contents intracellularly. Internalization of liposomes is dependent on many 
factors, such as liposome size, type of cell and type of target receptor [164-174].  
GPR-R is an example of an internalising receptor [175]. It has been shown that [D-Phe6, 
Sta13, Leu14]Bombesin(6-14), which is an antagonist can bind to GRP-R with high affinity 
(IC50 = 2.2 nM by competitive binding method) and internalize into the cell [50]. The 
radiolabelled (via 111In-DOTA-(β-Ala)2) peptide antagonist for GRP-R, [Cys5, D-Phe6, 
Sta13, Leu14]Bombesin(5-14) showed promising features. It showed high affinity (binding 
IC50 1.3 nM) to GRP-R in vitro using prostate cancer cell line (PC-3).  In another study, the 
internalization of a number of radio-analogues of the peptide was studied using a  
temperature shift experiment from 4 °C to 37 °C [176].  The internalized fraction after 4 h 
at 37C was less than 20% for the peptide radioanaloges, which is characteristic for 
antagonists. Biodistribution of the peptide in mice showed very high uptake of radioactivity 
in the GRP-R expressing  prostate cancer line (PC-3)  with high rate of clearance by kidney 
from non-malignant tissues [50, 177]. 
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The targeted liposomes would be expected to include on average 50% of the loaded targeting 
Cystabn-PEG-lipid conjugate on the liposome surface i.e. 19  μg/ml (15.6 µM) which is 
some 80-fold higher than the IC50 of this peptide for the GRP-receptor in Swiss 3T3 cells 
[48]. In addition to that, the targeted liposome formulation showed good stability in PBS and 
time-dependant stability in 10% FBS. When studied in vivo the metabolic stability of [Cys5, 
D-Phe6, Sta13, Leu14]Bombesin(5-14) it was reported that 60% of intact radiopeptides were 
still detectable after 5 min of injection using HPLC [50]. after 5 minutes, two major 
hydrophilic radiometabolites revealed. In summary, both control liposomes and cystabn-
targeted formulation failed to show significant internalisation into H345 SCLC cell. This is 
most likely attributable to an intrinsically low endocytic capacity in these cells. Future 
studies will seek to confirm the endocytic capacity of this cell line using robust fluorescent 
endocytic probes such as fluorescently labelled transferrin, dextrans and cholera toxin. 
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 Conclusion  
In this chapter, we have demonstrated that cystabn does not induce accelerated growth in 
A549 and NCI-H345 cells, both of which have been shown to express GRP-R to varying 
extents. Hence it is favourable to be used rather than GRP-R agonists, such as bombesin, for 
targeting functionality. GRP-R confirmed to be overexpressed on the surface of the SCLC 
cells (H345), which justifies targeting SCLC cells by targeting the receptor for delivery of 
drugs. Flow cytometry analysis of H345 cells showed that the extent of fluorescent liposome 
uptake was negligible over the time points tested, was equivalent for control and targeted 
formulations. This indicates that the current formulation approach is inappropriate for the 
preparation of targeted liposomes. Further work will focus on the confirmation of Cystabn 
uptake into both cell lines prior to formulation work to optimise the presentation of the 
targeting ligand on the liposome surface. With evidence of rapid peptide internalisation into 
the H345 and other SCLC cell lines further formulation work will be conducted to optimise 
ligand presentation to the GRP-R on the SCLC cell surface. 
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 General discussion 
In this study, the GRP-R expression measured. The idea of targeting this receptor came from 
its important role as autocrine growth factor in SCLC. Two lung cancer cells lines (SCLC 
and NSCLC) used in the study. The expression detected by indirect antibody measurement 
by flow cytometer. H345 cells showed higher surface expression of GRP-R (>2 fold, 
compared to A549), which suggest higher availability of the receptor.  A549 cells showed 
greater total amount of GRP-R. This could be explained as higher non-specific binding. This 
data support SCLC targeting using this receptor.  
Another important factor in targeting is the use of highly specific targeting moiety. In this 
study, an antagonist peptide (cystabn) was used for targeting as an alternative to bombesin 
(6-14) peptide. It has high affinity for GRP-R. the reason is that bombesin shown to cause 
cancer growth by autocrine manner. In addition, antagonistic peptide can cause tumour 
growth inhibition. Antagonistic peptide shown to not stimulate cell growth by using MTS 
proliferation assay. Cystabn synthesised by SPPS and successfully characterized by HPLC, 
MALDI-ToF MS and UV spectrometer. In addition to that, conjugation of the Cystabn 
peptide to DSPE-PEG-maleimide proceeded successfully to yield a peptide-PEG-lipid 
conjugate.  
Liposomes prepared by thin-film hydration as control liposome formulation (5% total 
DOPE-PEG) and targeted formulation (4% DOPE-PEG + 1% cystabn-PEG-DSPE). There 
was an increase in PDI and particle size over the 72 h time period for targeted liposome.  
This increase in size probably caused by opsonisation process. The characterization of the 
liposomes showed a monodisperse liposome suspension with a slightly negative zeta 
potential (-1.64 for control and -1.76 for targeted liposomes in PBS). The targeted liposome 
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formulation showed good stability in PBS and time-dependant stability in 10% FBS. The 
colloidal and biological stability of the system is provided through the steric hindrance effect 
caused by pegylation. Pegylation achieved by inclusion of 5 mole % DOPC-PEG2000. In this 
study, a 5 mole % pegylation is used to provide long circulation time in vivo by greatly 
decrease opsonisation.  
In this study, the internalization of cystabn targeted fluorescent liposomes to H345 cells in 
comparison to control was evaluated using flow cytometry. In general, the extent of liposome 
internalisation was low over the 120 min time course. In addition, there were no significant 
differences in cellular internalization between formulations over 120 min. However, there 
was observable increase in the MFI of both formulation and the control at 4 °C. Further 
investigation needed for the low cellular uptake.  
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 General conclusion  
In this study, we have demonstrated that GRP-R expressed on the surface of the SCLC cells 
higher than NSCLC cells. We have also demonstrated that cystabn does not induce growth 
in A549 and NCI-H345 cells. In addition to that, cystabn has high affinity and selectivity to 
the GRP-R. Therefore, the use of this antagonist is favourable over GRP-R agonists as a 
targeting moiety.  
Successful synthesis of cystabn, by SPPS and DSPE-PEG2000-cystabn conjugation is 
demonstrated. The characterization by three methods – HPLC, MALDI ToF and UV 
spectrometry – performed. The control and the targeted liposomes were synthesised and 
characterised by DLS. Both formulations showed monodispersed population. Further 
investigation into the stability of both formulation performed in PBS and 10% FBS. Both 
formulations showed good stability in PBS. The targeted formulation showed time-
dependant instability in 10% serum.   
Flow cytometry analysis of H345 cells showed internalization of both formulations 
compared to control cells at 4 °C. However, there was no significant diffrance between 
formulations. This indicates the need for invistgating other liposomes synthesis methods to 
improve the uptake.  
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